{"ticker": {"uuid": "3a7ae75a-339e-46b3-9acf-f0ebc63b0ca8", "symbol": "XRTX", "name": "XORTX Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "charts": {"tiers": [{"count": 24, "label": "Direct company coverage"}, {"count": 0, "label": "Industry context"}, {"count": 0, "label": "Sector context"}], "events": [{"count": 17, "label": "Market update"}, {"count": 3, "label": "Earnings"}, {"count": 3, "label": "Deals and strategy"}, {"count": 1, "label": "Regulatory and legal"}], "sources": [{"label": "Stock Titan", "count": 4}, {"label": "GlobeNewswire", "count": 3}, {"label": "kalkine.ca", "count": 3}, {"label": "TipRanks", "count": 2}, {"label": "Value Research", "count": 2}, {"label": "kalkine.com.au", "count": 1}, {"label": "StocksToTrade", "count": 1}, {"label": "finance.yahoo.com", "count": 1}]}, "insights": [{"text": "Early balanced news score", "tone": "neutral", "label": "Weighted tone", "value": "50/100"}, {"text": "1.94 effective stories after overlap and weighting.", "tone": "neutral", "label": "Evidence confidence", "value": "16/100"}, {"text": "Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.", "tone": "neutral", "label": "Market reaction", "value": "Early company-news score"}, {"text": "85/100 evidence concentration around this catalyst.", "tone": "neutral", "label": "Primary event", "value": "Market update"}, {"text": "100% of weighted evidence is company-specific.", "tone": "positive", "label": "Company focus", "value": "24"}, {"text": "lower dispersion means the independent stories agree more closely.", "tone": "positive", "label": "Evidence agreement", "value": "7/100"}, {"text": "-17.6% over one week, -5.9% over four weeks, trend inactive, and below fair value.", "tone": "negative", "label": "Trend context", "value": "Trend inactive"}, {"text": "XORTX Therapeutics Inc (NASDAQ: XRTX) Stock Price, News & Analysis", "tone": "neutral", "label": "Latest direct headline", "value": "Neutral"}], "classifier": {"events": [{"count": 17, "event": "general", "label": "Market update", "weight": 10.46}, {"count": 3, "event": "deals", "label": "Deals and strategy", "weight": 1.98}, {"count": 3, "event": "earnings", "label": "Earnings", "weight": 1.8}, {"count": 1, "event": "regulatory", "label": "Regulatory and legal", "weight": 0.6}], "pipeline": {"status": "partial", "providers_attempted": 4, "providers_with_results": 2, "raw_articles": 68, "unique_stories": 51, "duplicates_removed": 17, "relevant_stories": 24, "matched_archive_stories": 35, "current_evidence": 3, "direct_evidence": 24, "archive_articles": 17, "durable_story_count": 23, "durable_evidence_used": true, "durable_collected_at": "2026-09-24T02:04:31.295798+00:00"}, "confidence": 85, "primary_event": "general", "primary_label": "Market update", "negative_events": 0, "positive_events": 3}, "updated_at": "2026-09-25T10:23:29.212866+00:00", "total_unique": 24, "total_fetched": 24, "interpretation": {"tone": "neutral", "label": "Early company-news score", "risks": [], "badges": ["Provisional evidence"], "summary": "Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.", "confidence": 16, "event_label": "Market update", "opportunities": [], "classification": "provisional", "sentiment_word": "balanced"}, "market_context": {"trend_tone": "negative", "latest_week": "2026-09-18", "trend_label": "Trend inactive", "latest_close": 1.92, "trend_signal": "0", "one_week_move": -17.6, "reaction_tone": "negative", "fair_value_gap": -72.7, "four_week_move": -5.9, "reaction_label": "Price reacting lower", "fair_value_tone": "positive", "market_dynamics": 0.782784, "market_sentence": "-17.6% over one week, -5.9% over four weeks, trend inactive, and below fair value.", "fair_value_label": "Below fair value", "twelve_week_move": -12.3, "relative_strength": -34.256917, "has_market_context": true, "expectation_direction": "negative", "expectation_probability": 42.5907, "market_dynamics_buy_signal": false}, "total_relevant": 24, "pipeline_health": {"status": "partial", "providers_attempted": 4, "providers_with_results": 2, "raw_articles": 68, "unique_stories": 51, "duplicates_removed": 17, "relevant_stories": 24, "matched_archive_stories": 35, "current_evidence": 3, "direct_evidence": 24, "archive_articles": 17, "durable_story_count": 24, "durable_evidence_used": true, "durable_collected_at": "2026-09-25T10:23:29.212866+00:00"}, "sentiment_summary": {"tone": "neutral", "label": "Early balanced news score", "score": 50, "total": 24, "neutral": 21, "negative": 0, "positive": 3, "raw_score": 66, "confidence": 16, "dispersion": 7, "story_count": 24, "window_days": 30, "direct_share": 100, "source_count": 3, "score_version": "evidence-v10", "evidence_count": 3, "evidence_status": "provisional", "information_mass": 0.014, "weighting_method": "event-aware exponential freshness decay", "newest_article_at": "2026-09-18T20:29:00+00:00", "direct_story_count": 24, "effective_articles": 1.94, "sector_story_count": 0, "direct_source_count": 3, "industry_story_count": 0, "source_concentration": 0.5153, "directional_story_count": 3}, "articles": [{"url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE96OHJmU3ZWUXM2Y0drcmwtMzdHRnUtMmg2ejV0Y3ZvMEhtTHJUSVF0c010OS1xeTRHWWtyLXlBUXM4RGtfeDhRQ2hxdGo5N1VYS1djclJB?oc=5", "tier": "direct", "title": "XORTX Therapeutics Inc (NASDAQ: XRTX) Stock Price, News & Analysis", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "This article provides an overview of XORTX Therapeutics Inc (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on hyperuricemia-related diseases. It details their drug pipeline, including treatments for gout, autosomal dominant polycystic kidney disease, acute kidney injury, and type 2 diabetic nephropathy. The company's key financial metrics, income statements, balance sheets, and cash flow breakdowns for recent years are also presented, alongside a peer comparison in the biotechnology sector.", "age_days": 6.6, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE96OHJmU3ZWUXM2Y0drcmwtMzdHRnUtMmg2ejV0Y3ZvMEhtTHJUSVF0c010OS1xeTRHWWtyLXlBUXM4RGtfeDhRQ2hxdGo5N1VYS1djclJB?oc=5", "source_name": "kalkine.com.au", "published_at": "2026-09-18T20:29:00+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 40.2, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.038561, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "18 Sep 2026 20:29", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxQTW4wb2ZkMzBINnRVZ3ZOdWllV3I2RUw0MzdsYTFNamVfVy1GUE1HYVVHQkpMVnNEWW1oa2k5ZkxPa2hFLW9Ec1JlSTN4SkhoNUNrTU81aW1uN3J2Tmp2TXJLNFlRX2M3c0JjbHhycjV5Vnk1Y29wQm05SUkzZ01DSA?oc=5", "tier": "direct", "title": "XRTX Stock Whipsaws As XORTX Ramps Gout Drug Manufacturing", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "XORTX Therapeutics Inc. (NASDAQ: XRTX) shares have risen by 13.55% following positive developments for its lead kidney therapy. The company has initiated contract manufacturing for its XRx-026 gout program, moving closer to planned clinical trials and a future New Drug Application. This step, combined with governance clean-up efforts like delisting from TSX Venture Exchange and clarifying finder's fees, positions XRTX as a high-volatility, catalyst-driven stock for active traders.", "age_days": 6.7, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMigAFBVV95cUxQTW4wb2ZkMzBINnRVZ3ZOdWllV3I2RUw0MzdsYTFNamVfVy1GUE1HYVVHQkpMVnNEWW1oa2k5ZkxPa2hFLW9Ec1JlSTN4SkhoNUNrTU81aW1uN3J2Tmp2TXJLNFlRX2M3c0JjbHhycjV5Vnk1Y29wQm05SUkzZ01DSA?oc=5", "source_name": "StocksToTrade", "published_at": "2026-09-18T16:33:00+00:00", "tone_signals": ["Positive financial language"], "company_focus": 1.0, "freshness_pct": 39.3, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.042406, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "18 Sep 2026 16:33", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTFBTRmpNR0pxTENKVHJkWm4ydnhpLVFGWjNlTXM2TzVsbC0tOGE2aXBaNm0ycXhhQWJmRkNJSy1oSUNvbUZpc2VwWXhSb0lLQQ?oc=5", "tier": "direct", "title": "XORTX Therapeutics Inc. (XRTX) Stock Price, News, Quote & History", "topics": [], "summary": "", "age_days": 6.9, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "aggregator", "source_link": "https://news.google.com/rss/articles/CBMiTkFVX3lxTFBTRmpNR0pxTENKVHJkWm4ydnhpLVFGWjNlTXM2TzVsbC0tOGE2aXBaNm0ycXhhQWJmRkNJSy1oSUNvbUZpc2VwWXhSb0lLQQ?oc=5", "source_name": "finance.yahoo.com", "published_at": "2026-09-18T12:28:14+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 9.1, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.004465, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "18 Sep 2026 12:28", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOc0V3QWxaemQ4a2FMX3J3X2huN2I4cnkzS0pHY1FFYVU5M3VZZFVlQzlQZ0JGeGJpZVFCM09UX3preUVGeFNYMDB4NFI2QzltT2NrVDFyZ1NEbGdDQU5OSlNnY09wY0NXZThnTWV6OW5qZlY2T1FiU21uSG9XZ3VmWThyeVlsRXl3S1JWTVBfdzFMSVRlXzAtMDR1NkhEeEFfMlZMRlR3cWJTM1VoNTMzZzhpbVJOcXQzS1E?oc=5", "tier": "direct", "title": "A potential new gout pill targets a $700M market as XORTX Therapeutics (XRTX) details its FDA game plan", "topics": ["Life Sciences"], "summary": "XORTX Therapeutics Inc. (XRTX) is advancing its XRx-026 gout program, planning an Investigational New Drug (IND) submission to the FDA in Q4 2026 for its XORLO\u2122 formulation of oxypurinol. The company aims for a New Drug Application (NDA) submission approximately one year later, targeting an annual U.S. gout market opportunity of $700 million. XRx-026 is positioned as an alternative for patients who cannot tolerate existing treatments like allopurinol or are affected by febuxostat's cardiovascular warning.", "age_days": 6.9, "is_stale": false, "sentiment": "neutral", "event_type": "regulatory", "tier_label": "Direct company coverage", "event_label": "Regulatory and legal", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOc0V3QWxaemQ4a2FMX3J3X2huN2I4cnkzS0pHY1FFYVU5M3VZZFVlQzlQZ0JGeGJpZVFCM09UX3preUVGeFNYMDB4NFI2QzltT2NrVDFyZ1NEbGdDQU5OSlNnY09wY0NXZThnTWV6OW5qZlY2T1FiU21uSG9XZ3VmWThyeVlsRXl3S1JWTVBfdzFMSVRlXzAtMDR1NkhEeEFfMlZMRlR3cWJTM1VoNTMzZzhpbVJOcXQzS1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-09-18T12:05:37+00:00", "tone_signals": ["Negative financial language"], "company_focus": 1.0, "freshness_pct": 50.4, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.053595, "influence_label": "None", "event_confidence": 69, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "18 Sep 2026 12:05", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://finance.yahoo.com/healthcare/articles/xortx-announces-planned-fda-ind-120500476.html", "tier": "direct", "title": "XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO\u2122, Targeting USD$700M+ U.S. Gout Market Opportunity", "topics": [], "summary": "", "age_days": 6.9, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "press_release", "source_link": "https://finance.yahoo.com/healthcare/articles/xortx-announces-planned-fda-ind-120500476.html", "source_name": "GlobeNewswire", "published_at": "2026-09-18T12:05:00+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 9.1, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.005489, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "18 Sep 2026 12:05", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.benzinga.com/markets/equities/26/09/61731887/xortx-therapeutics-shares-rise-after-hours-manufacturing-milestone-gout-program", "tier": "direct", "title": "XORTX Therapeutics Shares Rise 16.11% After Hours - XORTX Therapeutics (NASDAQ:XRTX)", "topics": ["Financial Markets", "Life Sciences", "Manufacturing"], "summary": "XORTX Therapeutics (NASDAQ:XRTX) shares climbed 16.11% after hours following the announcement of a manufacturing milestone for its lead gout program, XRx-026. The company has begun production of drug material and tablets for XORLO\u2122, its proprietary oxypurinol formulation, to support a planned two-part clinical study. This move is a foundational step towards a future New Drug Application (NDA) submission to the FDA.", "age_days": 9.3, "is_stale": false, "sentiment": "positive", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.benzinga.com/markets/equities/26/09/61731887/xortx-therapeutics-shares-rise-after-hours-manufacturing-milestone-gout-program", "source_name": "Benzinga", "published_at": "2026-09-16T03:52:58+00:00", "tone_signals": ["Large positive market reaction", "Positive market reaction"], "company_focus": 1.0, "freshness_pct": 4.0, "sentiment_pct": 58, "evidence_basis": "archived_article", "evidence_share": 39.7, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.005736, "influence_label": "Medium", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 36, "published_display": "16 Sep 2026 03:52", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "39.7"}, {"url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTFBUYngyZnhXSGU4YXlWMEV1MENYYkMxVzZOQ1B1Y0JoZE15UWhZcDUwaUJpSU9HNTk1QUZUMlg3WG5JbGlFYTRoTVpXem45ZGxs?oc=5", "tier": "direct", "title": "XORTX Therapeutics Inc (NASDAQ: XRTX) Stock Price, News & Analysis", "topics": [], "summary": "", "age_days": 13.7, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiUEFVX3lxTFBUYngyZnhXSGU4YXlWMEV1MENYYkMxVzZOQ1B1Y0JoZE15UWhZcDUwaUJpSU9HNTk1QUZUMlg3WG5JbGlFYTRoTVpXem45ZGxs?oc=5", "source_name": "kalkine.ca", "published_at": "2026-09-11T18:13:00+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.9, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.000468, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "11 Sep 2026 18:13", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTFBTRmpNR0pxTENKVHJkWm4ydnhpLVFGWjNlTXM2TzVsbC0tOGE2aXBaNm0ycXhhQWJmRkNJSy1oSUNvbUZpc2VwWXhSb0lLQQ?oc=5", "tier": "direct", "title": "XORTX Therapeutics Inc. (XRTX) Stock Price, News, Quote & History", "topics": [], "summary": "", "age_days": 13.8, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "aggregator", "source_link": "https://news.google.com/rss/articles/CBMiTkFVX3lxTFBTRmpNR0pxTENKVHJkWm4ydnhpLVFGWjNlTXM2TzVsbC0tOGE2aXBaNm0ycXhhQWJmRkNJSy1oSUNvbUZpc2VwWXhSb0lLQQ?oc=5", "source_name": "Market source", "published_at": "2026-09-11T15:23:20+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.8, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.000412, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "11 Sep 2026 15:23", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.globenewswire.com/news-release/2026/09/10/3359975/0/en/xortx-announces-initiation-of-clinical-and-commercial-manufacturing-of-xorlo.html", "tier": "direct", "title": "XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO\u2122", "topics": ["Life Sciences", "Manufacturing"], "summary": "XORTX Therapeutics Inc. has started clinical and commercial manufacturing of XORLO\u2122, its proprietary oxypurinol formulation for gout treatment. This production supports the upcoming XRX-OXY-102 clinical study and aims for future US FDA marketing approval. The company is advancing its XRx-026 program, which includes manufacturing GMP drug substance and commercial-scale tablets, and expects validation and stability data to support its New Drug Application filing.", "age_days": 14.1, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "press_release", "source_link": "https://www.globenewswire.com/news-release/2026/09/10/3359975/0/en/xortx-announces-initiation-of-clinical-and-commercial-manufacturing-of-xorlo.html", "source_name": "GlobeNewswire", "published_at": "2026-09-11T09:11:16+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.8, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.000543, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "11 Sep 2026 09:11", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQeG9hTHF5aDZ3SVdRNTk4WHRabl9jUWtWa2tpTFp1d1dZQlBtajl0M05LeWZ0d1pNWWs3RENESHV4T2hGQldYejhld25SWnBic3JHWGtmUkZ2UzdCdGVPMDY1ODlSQkpyOUlrVGluM3YtZWMtMVRsZ3dJd09qTzZQRlZBNTMzaWdKOWFFbGpkN2NtVWVqZzBRcUFtV1doU0pxcGw5SjNVaDYzVHgxVzd1Wl9nX2NWckpqU2c?oc=5", "tier": "direct", "title": "XORTX Therapeutics (XRTX) begins making new gout drug", "topics": ["Life Sciences", "Manufacturing"], "summary": "XORTX Therapeutics Inc. (XRTX) has initiated the manufacturing of XORLO, its proprietary oxypurinol formulation for gout, to support the planned XRX-OXY-102 clinical study and future FDA marketing application. This move is a strategic priority for the company, aiming to address the unmet needs in gout treatment where current oral xanthine oxidase inhibitors have limitations. The manufacturing efforts are expected to generate validation and stability data crucial for a New Drug Application (NDA) filing.", "age_days": 14.6, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQeG9hTHF5aDZ3SVdRNTk4WHRabl9jUWtWa2tpTFp1d1dZQlBtajl0M05LeWZ0d1pNWWs3RENESHV4T2hGQldYejhld25SWnBic3JHWGtmUkZ2UzdCdGVPMDY1ODlSQkpyOUlrVGluM3YtZWMtMVRsZ3dJd09qTzZQRlZBNTMzaWdKOWFFbGpkN2NtVWVqZzBRcUFtV1doU0pxcGw5SjNVaDYzVHgxVzd1Wl9nX2NWckpqU2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-09-10T20:18:54+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.6, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.000398, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "10 Sep 2026 20:18", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxQemV2MHoxZk1NeE43dTlDODV5dGdITlZVWERIUDMyeTA2NU1VbmhwTnNoZGgtODVWQ0NhWUtFV3RLRDRiZGo5N0pialYzc1E4WGdkQjYyRVVON1c2YU0zdlA3TkkwRkVyUWJEWlh3XzQ4ZnNQY2VSdUpPd1lZUjlQa21USTF6MWtuMm9XVzJYZVNLYlk1ZkxJLUhGSk9wcTFyMC1UU04xX0JsMG9CVUxRc1p0RzNDLTFpRmJKb29Yc01TcHJMR052UHQ0cXU2TUpRYUtpcDdDTkN6Y2tjckFLMw?oc=5", "tier": "direct", "title": "XORTX Therapeutics Launches Clinical and Commercial Manufacturing of XORLO\u2122to Support Gout Treatment Program", "topics": [], "summary": "", "age_days": 15.1, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxQemV2MHoxZk1NeE43dTlDODV5dGdITlZVWERIUDMyeTA2NU1VbmhwTnNoZGgtODVWQ0NhWUtFV3RLRDRiZGo5N0pialYzc1E4WGdkQjYyRVVON1c2YU0zdlA3TkkwRkVyUWJEWlh3XzQ4ZnNQY2VSdUpPd1lZUjlQa21USTF6MWtuMm9XVzJYZVNLYlk1ZkxJLUhGSk9wcTFyMC1UU04xX0JsMG9CVUxRc1p0RzNDLTFpRmJKb29Yc01TcHJMR052UHQ0cXU2TUpRYUtpcDdDTkN6Y2tjckFLMw?oc=5", "source_name": "kalkine.ca", "published_at": "2026-09-10T07:00:00+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.5, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.000328, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "10 Sep 2026 07:00", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://markets.businessinsider.com/news/stocks/xortx-re-engages-investor-relations-program-1036530351", "tier": "direct", "title": "XORTX Re-Engages Investor Relations Program", "topics": ["Finance", "Life Sciences"], "summary": "XORTX Therapeutics Inc. has re-engaged IR Agency LLC for investor relations and marketing services following its voluntary delisting from the TSX Venture Exchange. The company, focused on developing treatments for gout, ADPKD, acute kidney injury, and diabetic nephropathy, aims to advance products targeting aberrant purine metabolism and xanthine oxidase. This re-engagement is under substantially similar terms to previously disclosed agreements, as XORTX continues to develop its pipeline of clinically advanced and pre-clinical stage programs.", "age_days": 16.0, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://markets.businessinsider.com/news/stocks/xortx-re-engages-investor-relations-program-1036530351", "source_name": "markets.businessinsider.com", "published_at": "2026-09-09T11:30:35+00:00", "tone_signals": [], "company_focus": 0.78, "freshness_pct": 0.4, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.00019, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 78, "evidence_strength": 0, "published_display": "09 Sep 2026 11:30", "direction_included": false, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.stocktitan.net/sec-filings/XRTX/6-k-xortx-therapeutics-inc-current-report-foreign-issuer-221218750f7b.html", "tier": "direct", "title": "XORTX Therapeutics (XRTX) commits $2.5M to investor outreach after TSXV delist", "topics": ["Finance", "Life Sciences"], "summary": "XORTX Therapeutics Inc. (XRTX) has re-engaged IR Agency LLC for investor relations and marketing services following its voluntary delisting from the TSX Venture Exchange. The three-month agreement, effective September 3, 2026, involves a US$2.5 million fee for up to ten news distribution campaigns, funded from previously returned fees from a terminated May 2026 agreement. This move aims to communicate company information to the financial community.", "age_days": 16.3, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.stocktitan.net/sec-filings/XRTX/6-k-xortx-therapeutics-inc-current-report-foreign-issuer-221218750f7b.html", "source_name": "Stock Titan", "published_at": "2026-09-09T03:52:58+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.4, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.000209, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "09 Sep 2026 03:52", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.tradingview.com/symbols/NASDAQ-XRTX/financials-statistics-and-ratios/price-sales-fwd", "tier": "direct", "title": "Price to sales forward of XORTX Therapeutics Inc. \u2013 NASDAQ:XRTX", "topics": ["Finance", "Financial Markets"], "summary": "The article focuses on XORTX Therapeutics Inc. (NASDAQ: XRTX) and its price to sales forward metric, as presented on TradingView. It appears to be a stub or a section of a larger financial data page, showing the company's stock market information and navigation links within the TradingView platform.", "age_days": 16.3, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.tradingview.com/symbols/NASDAQ-XRTX/financials-statistics-and-ratios/price-sales-fwd", "source_name": "TradingView", "published_at": "2026-09-09T03:52:58+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.4, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.000222, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "09 Sep 2026 03:52", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://kalkinemedia.com/us/news/announcements/xortx-therapeutics-nasdaq-xrtx-signs-new-25m-investor-relations-deal-with-ir-agency", "tier": "direct", "title": "XORTX Therapeutics (NASDAQ: XRTX) Signs New $2.5M Investor Relations Deal with IR Agency", "topics": ["Finance", "Financial Markets", "Life Sciences"], "summary": "XORTX Therapeutics (NASDAQ: XRTX) has entered into a new $2.5 million investor relations agreement with IR Agency for marketing and news distribution services, effective September 3, 2026. This move follows the company's voluntary delisting from the TSXV and aims to enhance its presence on the Nasdaq Capital Market. The contract, which is non-refundable upon payment, explicitly states that IR Agency does not guarantee increased trading volume or stock price for XRTX.", "age_days": 16.6, "is_stale": false, "sentiment": "neutral", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://kalkinemedia.com/us/news/announcements/xortx-therapeutics-nasdaq-xrtx-signs-new-25m-investor-relations-deal-with-ir-agency", "source_name": "Kalkine Media", "published_at": "2026-09-08T18:51:18+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 19.2, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.016619, "influence_label": "None", "event_confidence": 61, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "08 Sep 2026 18:51", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOMVR6US1lQWFOMDdiQXI1VzFNVmJMZFMtaTl5Ymp5QnBwenljaFlQVVdHT25uOU5UU2xKOWJEYXAyYjhzb3JIYkdtZWxSN1NIaTktRWlQYzJzbi1MdDNFbUtMdi1UWmN6RkFpN3E5NzNKdl95QlVCalo5Vnd5Ujd1NUpzak5XUkRKU05iWkRPRnFzbVdMYnpoNk01ZzNTOUhxTklNaHFDMDlfc3JNSkVhTG5SdExfUTQ2QjZOY3k3Z0dJazg2?oc=5", "tier": "direct", "title": "XORTX Therapeutics stock gains as Nasdaq listing takes center stage", "topics": [], "summary": "", "age_days": 19.9, "is_stale": false, "sentiment": "positive", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOMVR6US1lQWFOMDdiQXI1VzFNVmJMZFMtaTl5Ymp5QnBwenljaFlQVVdHT25uOU5UU2xKOWJEYXAyYjhzb3JIYkdtZWxSN1NIaTktRWlQYzJzbi1MdDNFbUtMdi1UWmN6RkFpN3E5NzNKdl95QlVCalo5Vnd5Ujd1NUpzak5XUkRKU05iWkRPRnFzbVdMYnpoNk01ZzNTOUhxTklNaHFDMDlfc3JNSkVhTG5SdExfUTQ2QjZOY3k3Z0dJazg2?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-09-05T12:05:55+00:00", "tone_signals": ["Positive financial language"], "company_focus": 1.0, "freshness_pct": 0.1, "sentiment_pct": 57, "evidence_basis": "headline_only", "evidence_share": 0.5, "score_included": true, "duplicate_count": 1, "evidence_weight": 7.4e-05, "influence_label": "Low", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 28, "published_display": "05 Sep 2026 12:05", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0.5"}, {"url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxNOU1hTUp1a0UyNkV1d011Yno5T2x3MDEzeVBENk1JaWRhVEsydHdsWFg0UERFTmd2UG1FZkxUZC1UdUpPYloxaG9BeVJ5V2RZQVZ0c2VzTkRoYldaaDZiX01mLTBBTURsc25XVmRCYU9zMm5OM19NZTlNNDFIRXpXSXFwOWpyY0k3bFI2dDM5MU1FYjVTaDVDd1VRcHl6eUhhYjZVeEVOSzhhZVZWaDNxc1dRYThzeWpuS1NHNXBwVGZ1WHRueGh6d0FfN2ZzUHFfUkdoRnM1aUlrUDhDZm9DdTNPSDFWZFczNzhfM2lUaW1SVjA?oc=5", "tier": "direct", "title": "XORTX Therapeutics Finalizes TSXV Delisting and Re-engages IR Agency in US$2.5 Million Nasdaq-Focused Campaign", "topics": [], "summary": "", "age_days": 20.8, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxNOU1hTUp1a0UyNkV1d011Yno5T2x3MDEzeVBENk1JaWRhVEsydHdsWFg0UERFTmd2UG1FZkxUZC1UdUpPYloxaG9BeVJ5V2RZQVZ0c2VzTkRoYldaaDZiX01mLTBBTURsc25XVmRCYU9zMm5OM19NZTlNNDFIRXpXSXFwOWpyY0k3bFI2dDM5MU1FYjVTaDVDd1VRcHl6eUhhYjZVeEVOSzhhZVZWaDNxc1dRYThzeWpuS1NHNXBwVGZ1WHRueGh6d0FfN2ZzUHFfUkdoRnM1aUlrUDhDZm9DdTNPSDFWZFczNzhfM2lUaW1SVjA?oc=5", "source_name": "TipRanks", "published_at": "2026-09-04T15:08:00+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.1, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 4.6e-05, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "04 Sep 2026 15:08", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPWTRZRnJ4cWltSVdnbTVBQ2xQV2Y2cFdxT2dTUjF1LTlEQmllSm1VdndZNExqbWQzY09mYzJXWGFoTHl2dmZBZnZvdTkydERmclEzcTMtdGo3V0lNcFRhMWF0d2k0ZV9GSEZpNDJseVNva2YtWU5ucjFnNjFFdWFSRzZnbHRFall3X3FWQ3RDenBGNnlXcHB5OEVWMi1MRThFdWRibFdTMWhKQ1dRRTNHU29yUncxeDZoY3hzX1BmMzUwenBCOW52Tg?oc=5", "tier": "direct", "title": "XORTX Therapeutics (XRTX) Advances 2.94% to $2.17 as Traders Eye Move Toward $2.28 Resistance - Overbought Signal Alerts", "topics": [], "summary": "", "age_days": 21.8, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPWTRZRnJ4cWltSVdnbTVBQ2xQV2Y2cFdxT2dTUjF1LTlEQmllSm1VdndZNExqbWQzY09mYzJXWGFoTHl2dmZBZnZvdTkydERmclEzcTMtdGo3V0lNcFRhMWF0d2k0ZV9GSEZpNDJseVNva2YtWU5ucjFnNjFFdWFSRzZnbHRFall3X3FWQ3RDenBGNnlXcHB5OEVWMi1MRThFdWRibFdTMWhKQ1dRRTNHU29yUncxeDZoY3hzX1BmMzUwenBCOW52Tg?oc=5", "source_name": "siam.in", "published_at": "2026-09-03T14:46:31+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.1, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 2.8e-05, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "03 Sep 2026 14:46", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxOSHZJRS1pZnBQME1pX2JxOTNzaDZtUnVOTW5xb1A4SFUzQy1BT2lRXzNOR2U2d3VxQ3hMNUtZQ3ZWN2pUY1FRVml6NFAwZ0NuWDhsQUF6MFRuLWlUN01Xa1h3T0hKblVOQnV5RGY5QTJPUldIMzZsbTl2M3ZoVFh5NmRLTlp3SThKR2phTExDSmNEYzRlSGcxY0NtanVKTXFhYUFiTkl0aG42UkNNN0tCTk8wcXNaVlFqaEJTVXQ0Vm56MDQ1eXZFZV8tREtURkJjM0M1cjVORnV4TlNsTk1IRXhCMVh5QQ?oc=5", "tier": "direct", "title": "XORTX Therapeutics (TSXV:XRTX) Gains 4.59% as Kidney-Disease Pipeline and Sharper Capital Focus Support Positive Momentum", "topics": ["Earnings", "Finance", "Financial Markets", "Life Sciences"], "summary": "XORTX Therapeutics (TSXV:XRTX) rose 4.59% on August 31, 2026, driven by increased investor interest in its kidney-disease pipeline and a sharper focus on capital preservation. The company's acquisition of an anti-fibrotic kidney asset and recent financing activities, coupled with the recovery of funds from a terminated investor-relations program, have strengthened its financial position. While the outlook is cautiously constructive, the company faces significant risks related to clinical execution, regulatory approval, and the capital-intensive nature of biotechnology development.", "age_days": 24.1, "is_stale": false, "sentiment": "positive", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxOSHZJRS1pZnBQME1pX2JxOTNzaDZtUnVOTW5xb1A4SFUzQy1BT2lRXzNOR2U2d3VxQ3hMNUtZQ3ZWN2pUY1FRVml6NFAwZ0NuWDhsQUF6MFRuLWlUN01Xa1h3T0hKblVOQnV5RGY5QTJPUldIMzZsbTl2M3ZoVFh5NmRLTlp3SThKR2phTExDSmNEYzRlSGcxY0NtanVKTXFhYUFiTkl0aG42UkNNN0tCTk8wcXNaVlFqaEJTVXQ0Vm56MDQ1eXZFZV8tREtURkJjM0M1cjVORnV4TlNsTk1IRXhCMVh5QQ?oc=5", "source_name": "kalkine.ca", "published_at": "2026-09-01T07:54:00+00:00", "tone_signals": ["Regulatory Approval"], "company_focus": 1.0, "freshness_pct": 3.5, "sentiment_pct": 71, "evidence_basis": "archived_article", "evidence_share": 59.8, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.008655, "influence_label": "Medium", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 51, "published_display": "01 Sep 2026 07:54", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "59.8"}, {"url": "https://www.tipranks.com/news/company-announcements/xortx-terminates-ir-agreement-postpones-marketing-amid-tsxv-delisting", "tier": "direct", "title": "XORTX Terminates IR Agreement, Postpones Marketing Amid TSXV Delisting", "topics": ["Earnings", "Finance", "Life Sciences"], "summary": "XORTX Therapeutics Inc. has terminated its investor relations agreement with IR Agency LLC, recovering a US$2.5 million prepaid fee. The company is postponing its marketing efforts and pursuing a voluntary delisting from the TSX Venture Exchange, effective September 1, 2026, to focus on business and clinical development. Additionally, XORTX corrected a prior disclosure regarding a US$240,000 finder's fee related to an acquisition.", "age_days": 27.4, "is_stale": false, "sentiment": "neutral", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://www.tipranks.com/news/company-announcements/xortx-terminates-ir-agreement-postpones-marketing-amid-tsxv-delisting", "source_name": "TipRanks", "published_at": "2026-08-29T00:37:11+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 6.6, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.006681, "influence_label": "None", "event_confidence": 77, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "29 Aug 2026 00:37", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNcTBrazllWEp1SXQxRTZnQ0R6ZENwTjRQNF9OSTNZcVAwcUN1NVlROFFSQzZoWUhyVERtUVVaS3VPZFRoRWhxTmg2NktKOVpNNVp3dmdiTHl2LVBmU1NPM0VheTY3Q0cwOGFtSUdIWjR4QUh5d2loM2RBa1N1LWVnTG5uS1V2V0p5d3F3NDJ5ZlhHWjV1dkVqVVprdkRQRTVPc2VXc3lnbHFkZUdrek5HTkkwZXpvbDByWkE?oc=5", "tier": "direct", "title": "XORTX Therapeutics (XRTX) to leave TSXV, delays $2.5M IR campaign", "topics": [], "summary": "", "age_days": 27.9, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNcTBrazllWEp1SXQxRTZnQ0R6ZENwTjRQNF9OSTNZcVAwcUN1NVlROFFSQzZoWUhyVERtUVVaS3VPZFRoRWhxTmg2NktKOVpNNVp3dmdiTHl2LVBmU1NPM0VheTY3Q0cwOGFtSUdIWjR4QUh5d2loM2RBa1N1LWVnTG5uS1V2V0p5d3F3NDJ5ZlhHWjV1dkVqVVprdkRQRTVPc2VXc3lnbHFkZUdrek5HTkkwZXpvbDByWkE?oc=5", "source_name": "Stock Titan", "published_at": "2026-08-28T12:45:39+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 3e-06, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "28 Aug 2026 12:45", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.globenewswire.com/news-release/2026/08/28/3352627/0/en/xortx-announces-termination-and-postponement-of-investor-relations-program.html", "tier": "direct", "title": "XORTX Announces Termination and Postponement of Investor Relations Program", "topics": ["Finance", "Life Sciences"], "summary": "XORTX Therapeutics Inc. has terminated its investor relations agreement with IR Agency LLC and postponed its marketing program. This decision was made to reduce regulatory complexity and focus resources while the company voluntarily delists from the TSX Venture Exchange, a process expected to complete by September 1, 2026. XORTX also disclosed finder's fees paid for a previous acquisition and announced a change in its transfer agent.", "age_days": 28.1, "is_stale": false, "sentiment": "neutral", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "press_release", "source_link": "https://www.globenewswire.com/news-release/2026/08/28/3352627/0/en/xortx-announces-termination-and-postponement-of-investor-relations-program.html", "source_name": "GlobeNewswire", "published_at": "2026-08-28T07:00:00+00:00", "tone_signals": ["Negative financial language"], "company_focus": 1.0, "freshness_pct": 6.2, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.006789, "influence_label": "None", "event_confidence": 77, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "28 Aug 2026 07:00", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPWVQwV09QVHlIMTNXbmFsd1htbXBZY1Zxd29KNkR6ejBzSlZJT1MtLXdSdl9VSFBzRzgtaldhS09HY3hGVlV3TXd3d095blpUeEQwclNpb3NtTWUtclVNZnBEeUpFdWpRM0RSSjFPUUlSY0JpMUU3SHI0UEpTdU1UNTljS1NDaVo4WllZUFFaWjdHMFJCX0xoMnE1M1RtV0Vqak9ZdGlscFM5S3M?oc=5", "tier": "direct", "title": "XORTX Therapeutics Inc. (XRTX) Peer Comparison \u2013 Compare with Others", "topics": [], "summary": "", "age_days": 28.6, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPWVQwV09QVHlIMTNXbmFsd1htbXBZY1Zxd29KNkR6ejBzSlZJT1MtLXdSdl9VSFBzRzgtaldhS09HY3hGVlV3TXd3d095blpUeEQwclNpb3NtTWUtclVNZnBEeUpFdWpRM0RSSjFPUUlSY0JpMUU3SHI0UEpTdU1UNTljS1NDaVo4WllZUFFaWjdHMFJCX0xoMnE1M1RtV0Vqak9ZdGlscFM5S3M?oc=5", "source_name": "Value Research", "published_at": "2026-08-27T20:01:00+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 3e-06, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "27 Aug 2026 20:01", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPZFRHLUtFR1dlZ05YN1RHc2NGQ2pjRG85dWlfR19nc2Q0aUdtRHpjbk9LbkhfWmlDa25tbXNHYkdBMmp0bmJUcHQteER6UWl2QUROZFgzTjhaSE0teGdnZmd6SVR0TzIwNVhKXzVXMGxRenZpY3YzcF9DcUFjNWZaMk1aMkoxR2xGS2JQNF9mbUVIQ2cxYTBfR2g2VDlXT1lMWnZpQg?oc=5", "tier": "direct", "title": "XORTX Therapeutics Inc. (XRTX) Key Financial Ratios \u2013 Valuation, Profitability & More", "topics": [], "summary": "", "age_days": 28.6, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPZFRHLUtFR1dlZ05YN1RHc2NGQ2pjRG85dWlfR19nc2Q0aUdtRHpjbk9LbkhfWmlDa25tbXNHYkdBMmp0bmJUcHQteER6UWl2QUROZFgzTjhaSE0teGdnZmd6SVR0TzIwNVhKXzVXMGxRenZpY3YzcF9DcUFjNWZaMk1aMkoxR2xGS2JQNF9mbUVIQ2cxYTBfR2g2VDlXT1lMWnZpQg?oc=5", "source_name": "Value Research", "published_at": "2026-08-27T20:01:00+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 3e-06, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "27 Aug 2026 20:01", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}], "by_tier": {"direct": [{"url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE96OHJmU3ZWUXM2Y0drcmwtMzdHRnUtMmg2ejV0Y3ZvMEhtTHJUSVF0c010OS1xeTRHWWtyLXlBUXM4RGtfeDhRQ2hxdGo5N1VYS1djclJB?oc=5", "tier": "direct", "title": "XORTX Therapeutics Inc (NASDAQ: XRTX) Stock Price, News & Analysis", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "This article provides an overview of XORTX Therapeutics Inc (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on hyperuricemia-related diseases. It details their drug pipeline, including treatments for gout, autosomal dominant polycystic kidney disease, acute kidney injury, and type 2 diabetic nephropathy. The company's key financial metrics, income statements, balance sheets, and cash flow breakdowns for recent years are also presented, alongside a peer comparison in the biotechnology sector.", "age_days": 6.6, "is_stale": false, "provider": "google_news", "providers": ["alphavantage", "google_news"], "sentiment": "neutral", "story_key": "aac212032a6b8f18415d3b8e01f20ff45a19bf8d88954dca3c15555600e0bb90", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE96OHJmU3ZWUXM2Y0drcmwtMzdHRnUtMmg2ejV0Y3ZvMEhtTHJUSVF0c010OS1xeTRHWWtyLXlBUXM4RGtfeDhRQ2hxdGo5N1VYS1djclJB?oc=5", "source_name": "kalkine.com.au", "published_at": "2026-09-18T20:29:00+00:00", "source_names": ["kalkine.ca", "kalkine.com.au"], "target_scope": "XORTX Therapeutics Inc (NASDAQ: XRTX) Stock Price, News & Analysis This article provides an overview of XORTX Therapeutics Inc (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on hyperuricemia-related diseases.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 40.2, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.038561, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["XRTX", "XRTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "18 Sep 2026 20:29", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "XRTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxQTW4wb2ZkMzBINnRVZ3ZOdWllV3I2RUw0MzdsYTFNamVfVy1GUE1HYVVHQkpMVnNEWW1oa2k5ZkxPa2hFLW9Ec1JlSTN4SkhoNUNrTU81aW1uN3J2Tmp2TXJLNFlRX2M3c0JjbHhycjV5Vnk1Y29wQm05SUkzZ01DSA?oc=5", "tier": "direct", "title": "XRTX Stock Whipsaws As XORTX Ramps Gout Drug Manufacturing", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "XORTX Therapeutics Inc. (NASDAQ: XRTX) shares have risen by 13.55% following positive developments for its lead kidney therapy. The company has initiated contract manufacturing for its XRx-026 gout program, moving closer to planned clinical trials and a future New Drug Application. This step, combined with governance clean-up efforts like delisting from TSX Venture Exchange and clarifying finder's fees, positions XRTX as a high-volatility, catalyst-driven stock for active traders.", "age_days": 6.7, "is_stale": false, "provider": "google_news", "providers": ["alphavantage", "google_news"], "sentiment": "neutral", "story_key": "41f9b2cdad5e274ec190bb730e315041bd50f76f5e81950162704b3d692d4eed", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMigAFBVV95cUxQTW4wb2ZkMzBINnRVZ3ZOdWllV3I2RUw0MzdsYTFNamVfVy1GUE1HYVVHQkpMVnNEWW1oa2k5ZkxPa2hFLW9Ec1JlSTN4SkhoNUNrTU81aW1uN3J2Tmp2TXJLNFlRX2M3c0JjbHhycjV5Vnk1Y29wQm05SUkzZ01DSA?oc=5", "source_name": "StocksToTrade", "published_at": "2026-09-18T16:33:00+00:00", "source_names": ["StocksToTrade"], "target_scope": "XRTX Stock Whipsaws As XORTX Ramps Gout Drug Manufacturing XORTX Therapeutics Inc. (NASDAQ: XRTX) shares have risen by 13.55% following positive developments for its lead kidney therapy. This step, combined with governance clean-up efforts like delisting from TSX Venture Exchange and clarifying finder's fees, positions XRTX as a high-volatility, catalyst-driven stock for active traders.", "tone_signals": ["Positive financial language"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 39.3, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.042406, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.45, "provider_symbols": ["XRTX", "XRTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "18 Sep 2026 16:33", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "XRTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTFBTRmpNR0pxTENKVHJkWm4ydnhpLVFGWjNlTXM2TzVsbC0tOGE2aXBaNm0ycXhhQWJmRkNJSy1oSUNvbUZpc2VwWXhSb0lLQQ?oc=5", "tier": "direct", "title": "XORTX Therapeutics Inc. (XRTX) Stock Price, News, Quote & History", "topics": [], "summary": "", "age_days": 6.9, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "neutral", "story_key": "68e5e658b2c9cca1ce5498d877da825fe79e9d96a9948fc137ac55bb98d51419", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "aggregator", "source_link": "https://news.google.com/rss/articles/CBMiTkFVX3lxTFBTRmpNR0pxTENKVHJkWm4ydnhpLVFGWjNlTXM2TzVsbC0tOGE2aXBaNm0ycXhhQWJmRkNJSy1oSUNvbUZpc2VwWXhSb0lLQQ?oc=5", "source_name": "finance.yahoo.com", "published_at": "2026-09-18T12:28:14+00:00", "source_names": ["finance.yahoo.com"], "target_scope": "XORTX Therapeutics Inc. (XRTX) Stock Price, News, Quote & History", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 9.1, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.004465, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["XRTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "18 Sep 2026 12:28", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "XRTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOc0V3QWxaemQ4a2FMX3J3X2huN2I4cnkzS0pHY1FFYVU5M3VZZFVlQzlQZ0JGeGJpZVFCM09UX3preUVGeFNYMDB4NFI2QzltT2NrVDFyZ1NEbGdDQU5OSlNnY09wY0NXZThnTWV6OW5qZlY2T1FiU21uSG9XZ3VmWThyeVlsRXl3S1JWTVBfdzFMSVRlXzAtMDR1NkhEeEFfMlZMRlR3cWJTM1VoNTMzZzhpbVJOcXQzS1E?oc=5", "tier": "direct", "title": "A potential new gout pill targets a $700M market as XORTX Therapeutics (XRTX) details its FDA game plan", "topics": ["Life Sciences"], "summary": "XORTX Therapeutics Inc. (XRTX) is advancing its XRx-026 gout program, planning an Investigational New Drug (IND) submission to the FDA in Q4 2026 for its XORLO\u2122 formulation of oxypurinol. The company aims for a New Drug Application (NDA) submission approximately one year later, targeting an annual U.S. gout market opportunity of $700 million. XRx-026 is positioned as an alternative for patients who cannot tolerate existing treatments like allopurinol or are affected by febuxostat's cardiovascular warning.", "age_days": 6.9, "is_stale": false, "provider": "google_news", "providers": ["alphavantage", "google_news"], "sentiment": "neutral", "story_key": "e157bc10e9312a8f0ebcc2713dc34cb314e608a5bdec1391df59b84bac5dc651", "event_type": "regulatory", "tier_label": "Direct company coverage", "event_label": "Regulatory and legal", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOc0V3QWxaemQ4a2FMX3J3X2huN2I4cnkzS0pHY1FFYVU5M3VZZFVlQzlQZ0JGeGJpZVFCM09UX3preUVGeFNYMDB4NFI2QzltT2NrVDFyZ1NEbGdDQU5OSlNnY09wY0NXZThnTWV6OW5qZlY2T1FiU21uSG9XZ3VmWThyeVlsRXl3S1JWTVBfdzFMSVRlXzAtMDR1NkhEeEFfMlZMRlR3cWJTM1VoNTMzZzhpbVJOcXQzS1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-09-18T12:05:37+00:00", "source_names": ["Stock Titan"], "target_scope": "A potential new gout pill targets a $700M market as XORTX Therapeutics (XRTX) details its FDA game plan XORTX Therapeutics Inc. (XRTX) is advancing its XRx-026 gout program, planning an Investigational New Drug (IND) submission to the FDA in Q4 2026 for its XORLO\u2122 formulation of oxypurinol.", "tone_signals": ["Negative financial language"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 50.4, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.053595, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 69, "model_confidence": 0.45, "provider_symbols": ["XRTX", "XRTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "18 Sep 2026 12:05", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "XRTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://finance.yahoo.com/healthcare/articles/xortx-announces-planned-fda-ind-120500476.html", "tier": "direct", "title": "XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO\u2122, Targeting USD$700M+ U.S. Gout Market Opportunity", "topics": [], "summary": "", "age_days": 6.9, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "neutral", "story_key": "2c430382c9ff9834b2d3c400830b04c0a7090643d8d7171665fe3dbd8cdf87db", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "press_release", "source_link": "https://finance.yahoo.com/healthcare/articles/xortx-announces-planned-fda-ind-120500476.html", "source_name": "GlobeNewswire", "published_at": "2026-09-18T12:05:00+00:00", "source_names": ["GlobeNewswire"], "target_scope": "XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO\u2122, Targeting USD$700M+ U.S.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 9.1, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.005489, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "yfinance", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["XRTX", "XRTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "18 Sep 2026 12:05", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "XRTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://www.benzinga.com/markets/equities/26/09/61731887/xortx-therapeutics-shares-rise-after-hours-manufacturing-milestone-gout-program", "tier": "direct", "title": "XORTX Therapeutics Shares Rise 16.11% After Hours - XORTX Therapeutics (NASDAQ:XRTX)", "topics": ["Financial Markets", "Life Sciences", "Manufacturing"], "summary": "XORTX Therapeutics (NASDAQ:XRTX) shares climbed 16.11% after hours following the announcement of a manufacturing milestone for its lead gout program, XRx-026. The company has begun production of drug material and tablets for XORLO\u2122, its proprietary oxypurinol formulation, to support a planned two-part clinical study. This move is a foundational step towards a future New Drug Application (NDA) submission to the FDA.", "age_days": 9.3, "is_stale": false, "provider": "archive", "providers": ["alphavantage", "archive"], "sentiment": "positive", "story_key": "9150574ee456253de30f5d1416e44e7141b12767786ca1dd06034de46840bfc3", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.benzinga.com/markets/equities/26/09/61731887/xortx-therapeutics-shares-rise-after-hours-manufacturing-milestone-gout-program", "source_name": "Benzinga", "published_at": "2026-09-16T03:52:58+00:00", "source_names": ["Benzinga"], "target_scope": "XORTX Therapeutics Shares Rise 16.11% After Hours - XORTX Therapeutics (NASDAQ:XRTX) XORTX Therapeutics (NASDAQ:XRTX) shares climbed 16.11% after hours following the announcement of a manufacturing milestone for its lead gout program, XRx-026.", "tone_signals": ["Large positive market reaction", "Positive market reaction"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 4.0, "sentiment_pct": 58, "evidence_basis": "archived_article", "evidence_share": 39.7, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.005736, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "alphavantage", "event_confidence": 35, "model_confidence": 0.63, "provider_symbols": ["XRTX", "XRTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 36, "published_display": "16 Sep 2026 03:52", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "39.7", "target_provider_symbol": "XRTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTFBUYngyZnhXSGU4YXlWMEV1MENYYkMxVzZOQ1B1Y0JoZE15UWhZcDUwaUJpSU9HNTk1QUZUMlg3WG5JbGlFYTRoTVpXem45ZGxs?oc=5", "tier": "direct", "title": "XORTX Therapeutics Inc (NASDAQ: XRTX) Stock Price, News & Analysis", "topics": [], "summary": "", "age_days": 13.7, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "neutral", "story_key": "aac212032a6b8f18415d3b8e01f20ff45a19bf8d88954dca3c15555600e0bb90", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiUEFVX3lxTFBUYngyZnhXSGU4YXlWMEV1MENYYkMxVzZOQ1B1Y0JoZE15UWhZcDUwaUJpSU9HNTk1QUZUMlg3WG5JbGlFYTRoTVpXem45ZGxs?oc=5", "source_name": "kalkine.ca", "published_at": "2026-09-11T18:13:00+00:00", "source_names": ["kalkine.ca"], "target_scope": "XORTX Therapeutics Inc (NASDAQ: XRTX) Stock Price, News & Analysis", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.9, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.000468, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["XRTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "11 Sep 2026 18:13", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "XRTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTFBTRmpNR0pxTENKVHJkWm4ydnhpLVFGWjNlTXM2TzVsbC0tOGE2aXBaNm0ycXhhQWJmRkNJSy1oSUNvbUZpc2VwWXhSb0lLQQ?oc=5", "tier": "direct", "title": "XORTX Therapeutics Inc. (XRTX) Stock Price, News, Quote & History", "topics": [], "summary": "", "age_days": 13.8, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "neutral", "story_key": "68e5e658b2c9cca1ce5498d877da825fe79e9d96a9948fc137ac55bb98d51419", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "aggregator", "source_link": "https://news.google.com/rss/articles/CBMiTkFVX3lxTFBTRmpNR0pxTENKVHJkWm4ydnhpLVFGWjNlTXM2TzVsbC0tOGE2aXBaNm0ycXhhQWJmRkNJSy1oSUNvbUZpc2VwWXhSb0lLQQ?oc=5", "source_name": "Market source", "published_at": "2026-09-11T15:23:20+00:00", "source_names": ["Market source"], "target_scope": "XORTX Therapeutics Inc. (XRTX) Stock Price, News, Quote & History", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.8, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.000412, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["XRTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "11 Sep 2026 15:23", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "XRTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://www.globenewswire.com/news-release/2026/09/10/3359975/0/en/xortx-announces-initiation-of-clinical-and-commercial-manufacturing-of-xorlo.html", "tier": "direct", "title": "XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO\u2122", "topics": ["Life Sciences", "Manufacturing"], "summary": "XORTX Therapeutics Inc. has started clinical and commercial manufacturing of XORLO\u2122, its proprietary oxypurinol formulation for gout treatment. This production supports the upcoming XRX-OXY-102 clinical study and aims for future US FDA marketing approval. The company is advancing its XRx-026 program, which includes manufacturing GMP drug substance and commercial-scale tablets, and expects validation and stability data to support its New Drug Application filing.", "age_days": 14.1, "is_stale": false, "provider": "archive", "providers": ["alphavantage", "archive"], "sentiment": "neutral", "story_key": "5b44f43c0b416a7f4df275a82adccc849b17333489f45e33d069d33998c2481e", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "press_release", "source_link": "https://www.globenewswire.com/news-release/2026/09/10/3359975/0/en/xortx-announces-initiation-of-clinical-and-commercial-manufacturing-of-xorlo.html", "source_name": "GlobeNewswire", "published_at": "2026-09-11T09:11:16+00:00", "source_names": ["GlobeNewswire"], "target_scope": "XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO\u2122 XORTX Therapeutics Inc.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.8, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.000543, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "alphavantage", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["XRTX", "XRTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "11 Sep 2026 09:11", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "XRTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQeG9hTHF5aDZ3SVdRNTk4WHRabl9jUWtWa2tpTFp1d1dZQlBtajl0M05LeWZ0d1pNWWs3RENESHV4T2hGQldYejhld25SWnBic3JHWGtmUkZ2UzdCdGVPMDY1ODlSQkpyOUlrVGluM3YtZWMtMVRsZ3dJd09qTzZQRlZBNTMzaWdKOWFFbGpkN2NtVWVqZzBRcUFtV1doU0pxcGw5SjNVaDYzVHgxVzd1Wl9nX2NWckpqU2c?oc=5", "tier": "direct", "title": "XORTX Therapeutics (XRTX) begins making new gout drug", "topics": ["Life Sciences", "Manufacturing"], "summary": "XORTX Therapeutics Inc. (XRTX) has initiated the manufacturing of XORLO, its proprietary oxypurinol formulation for gout, to support the planned XRX-OXY-102 clinical study and future FDA marketing application. This move is a strategic priority for the company, aiming to address the unmet needs in gout treatment where current oral xanthine oxidase inhibitors have limitations. The manufacturing efforts are expected to generate validation and stability data crucial for a New Drug Application (NDA) filing.", "age_days": 14.6, "is_stale": false, "provider": "google_news", "providers": ["alphavantage", "google_news"], "sentiment": "neutral", "story_key": "f450a885ef05b2af2db9dcbedd8adc8761b90988685ec36780b21c79e1951f30", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQeG9hTHF5aDZ3SVdRNTk4WHRabl9jUWtWa2tpTFp1d1dZQlBtajl0M05LeWZ0d1pNWWs3RENESHV4T2hGQldYejhld25SWnBic3JHWGtmUkZ2UzdCdGVPMDY1ODlSQkpyOUlrVGluM3YtZWMtMVRsZ3dJd09qTzZQRlZBNTMzaWdKOWFFbGpkN2NtVWVqZzBRcUFtV1doU0pxcGw5SjNVaDYzVHgxVzd1Wl9nX2NWckpqU2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-09-10T20:18:54+00:00", "source_names": ["Stock Titan"], "target_scope": "XORTX Therapeutics (XRTX) begins making new gout drug XORTX Therapeutics Inc. (XRTX) has initiated the manufacturing of XORLO, its proprietary oxypurinol formulation for gout, to support the planned XRX-OXY-102 clinical study and future FDA marketing application.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.6, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.000398, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["XRTX", "XRTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "10 Sep 2026 20:18", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "XRTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxQemV2MHoxZk1NeE43dTlDODV5dGdITlZVWERIUDMyeTA2NU1VbmhwTnNoZGgtODVWQ0NhWUtFV3RLRDRiZGo5N0pialYzc1E4WGdkQjYyRVVON1c2YU0zdlA3TkkwRkVyUWJEWlh3XzQ4ZnNQY2VSdUpPd1lZUjlQa21USTF6MWtuMm9XVzJYZVNLYlk1ZkxJLUhGSk9wcTFyMC1UU04xX0JsMG9CVUxRc1p0RzNDLTFpRmJKb29Yc01TcHJMR052UHQ0cXU2TUpRYUtpcDdDTkN6Y2tjckFLMw?oc=5", "tier": "direct", "title": "XORTX Therapeutics Launches Clinical and Commercial Manufacturing of XORLO\u2122to Support Gout Treatment Program", "topics": [], "summary": "", "age_days": 15.1, "is_stale": false, "provider": "google_news", "providers": ["google_news"], "sentiment": "neutral", "story_key": "644e5f4c725442bd04842b94035fbda82795fd6b32aecf27d6bd02d4a1e3586c", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxQemV2MHoxZk1NeE43dTlDODV5dGdITlZVWERIUDMyeTA2NU1VbmhwTnNoZGgtODVWQ0NhWUtFV3RLRDRiZGo5N0pialYzc1E4WGdkQjYyRVVON1c2YU0zdlA3TkkwRkVyUWJEWlh3XzQ4ZnNQY2VSdUpPd1lZUjlQa21USTF6MWtuMm9XVzJYZVNLYlk1ZkxJLUhGSk9wcTFyMC1UU04xX0JsMG9CVUxRc1p0RzNDLTFpRmJKb29Yc01TcHJMR052UHQ0cXU2TUpRYUtpcDdDTkN6Y2tjckFLMw?oc=5", "source_name": "kalkine.ca", "published_at": "2026-09-10T07:00:00+00:00", "source_names": ["kalkine.ca"], "target_scope": "", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": false, "freshness_pct": 0.5, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.000328, "influence_label": "None", "provider_symbol": "", "relevance_score": null, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": [], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "10 Sep 2026 07:00", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "", "provider_directional_mass": null}, {"url": "https://markets.businessinsider.com/news/stocks/xortx-re-engages-investor-relations-program-1036530351", "tier": "direct", "title": "XORTX Re-Engages Investor Relations Program", "topics": ["Finance", "Life Sciences"], "summary": "XORTX Therapeutics Inc. has re-engaged IR Agency LLC for investor relations and marketing services following its voluntary delisting from the TSX Venture Exchange. The company, focused on developing treatments for gout, ADPKD, acute kidney injury, and diabetic nephropathy, aims to advance products targeting aberrant purine metabolism and xanthine oxidase. This re-engagement is under substantially similar terms to previously disclosed agreements, as XORTX continues to develop its pipeline of clinically advanced and pre-clinical stage programs.", "age_days": 16.0, "is_stale": false, "provider": "archive", "providers": ["alphavantage", "archive"], "sentiment": "neutral", "story_key": "14d33608a38c074cf0b244165e71ce46febe42dc4cd4b52933d2288853ffb541", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://markets.businessinsider.com/news/stocks/xortx-re-engages-investor-relations-program-1036530351", "source_name": "markets.businessinsider.com", "published_at": "2026-09-09T11:30:35+00:00", "source_names": ["markets.businessinsider.com"], "target_scope": "XORTX Re-Engages Investor Relations Program XORTX Therapeutics Inc. This re-engagement is under substantially similar terms to previously disclosed agreements, as XORTX continues to develop its pipeline of clinically advanced and pre-clinical stage programs.", "tone_signals": [], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.4, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.00019, "influence_label": "None", "provider_symbol": "XRTX.US", "relevance_score": 1.0, "archive_provider": "alphavantage", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["0512.HK", "XRTX", "XRTX.ARCHIVE", "XRTX.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 0, "published_display": "09 Sep 2026 11:30", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "XRTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://www.stocktitan.net/sec-filings/XRTX/6-k-xortx-therapeutics-inc-current-report-foreign-issuer-221218750f7b.html", "tier": "direct", "title": "XORTX Therapeutics (XRTX) commits $2.5M to investor outreach after TSXV delist", "topics": ["Finance", "Life Sciences"], "summary": "XORTX Therapeutics Inc. (XRTX) has re-engaged IR Agency LLC for investor relations and marketing services following its voluntary delisting from the TSX Venture Exchange. The three-month agreement, effective September 3, 2026, involves a US$2.5 million fee for up to ten news distribution campaigns, funded from previously returned fees from a terminated May 2026 agreement. This move aims to communicate company information to the financial community.", "age_days": 16.3, "is_stale": false, "provider": "archive", "providers": ["alphavantage", "archive"], "sentiment": "neutral", "story_key": "d6b53af010046e9d4bb269765777a821a3c4bf55e35d7f1b0f5fc7a54ed2131f", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.stocktitan.net/sec-filings/XRTX/6-k-xortx-therapeutics-inc-current-report-foreign-issuer-221218750f7b.html", "source_name": "Stock Titan", "published_at": "2026-09-09T03:52:58+00:00", "source_names": ["Stock Titan"], "target_scope": "XORTX Therapeutics (XRTX) commits $2.5M to investor outreach after TSXV delist XORTX Therapeutics Inc. (XRTX) has re-engaged IR Agency LLC for investor relations and marketing services following its voluntary delisting from the TSX Venture Exchange.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.4, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.000209, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.91298, "archive_provider": "alphavantage", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["XRTX", "XRTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "09 Sep 2026 03:52", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "XRTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://www.tradingview.com/symbols/NASDAQ-XRTX/financials-statistics-and-ratios/price-sales-fwd", "tier": "direct", "title": "Price to sales forward of XORTX Therapeutics Inc. \u2013 NASDAQ:XRTX", "topics": ["Finance", "Financial Markets"], "summary": "The article focuses on XORTX Therapeutics Inc. (NASDAQ: XRTX) and its price to sales forward metric, as presented on TradingView. It appears to be a stub or a section of a larger financial data page, showing the company's stock market information and navigation links within the TradingView platform.", "age_days": 16.3, "is_stale": false, "provider": "archive", "providers": ["alphavantage", "archive"], "sentiment": "neutral", "story_key": "0052754e2793c7653a13cfd97dcb1143c1796362c8fecadf38a061b4fe413cbb", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.tradingview.com/symbols/NASDAQ-XRTX/financials-statistics-and-ratios/price-sales-fwd", "source_name": "TradingView", "published_at": "2026-09-09T03:52:58+00:00", "source_names": ["TradingView"], "target_scope": "Price to sales forward of XORTX Therapeutics Inc. \u2013 NASDAQ:XRTX The article focuses on XORTX Therapeutics Inc. (NASDAQ: XRTX) and its price to sales forward metric, as presented on TradingView.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.4, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.000222, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "alphavantage", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["XRTX", "XRTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "09 Sep 2026 03:52", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "XRTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://kalkinemedia.com/us/news/announcements/xortx-therapeutics-nasdaq-xrtx-signs-new-25m-investor-relations-deal-with-ir-agency", "tier": "direct", "title": "XORTX Therapeutics (NASDAQ: XRTX) Signs New $2.5M Investor Relations Deal with IR Agency", "topics": ["Finance", "Financial Markets", "Life Sciences"], "summary": "XORTX Therapeutics (NASDAQ: XRTX) has entered into a new $2.5 million investor relations agreement with IR Agency for marketing and news distribution services, effective September 3, 2026. This move follows the company's voluntary delisting from the TSXV and aims to enhance its presence on the Nasdaq Capital Market. The contract, which is non-refundable upon payment, explicitly states that IR Agency does not guarantee increased trading volume or stock price for XRTX.", "age_days": 16.6, "is_stale": false, "provider": "archive", "providers": ["alphavantage", "archive"], "sentiment": "neutral", "story_key": "7c2b5802cc2660fbfd473bc9201a2cb379f0b35949e1c1c814e0d6944651ab28", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://kalkinemedia.com/us/news/announcements/xortx-therapeutics-nasdaq-xrtx-signs-new-25m-investor-relations-deal-with-ir-agency", "source_name": "Kalkine Media", "published_at": "2026-09-08T18:51:18+00:00", "source_names": ["Kalkine Media"], "target_scope": "XORTX Therapeutics (NASDAQ: XRTX) Signs New $2.5M Investor Relations Deal with IR Agency XORTX Therapeutics (NASDAQ: XRTX) has entered into a new $2.5 million investor relations agreement with IR Agency for marketing and news distribution services, effective September 3, 2026. The contract, which is non-refundable upon payment, explicitly states that IR Agency does not guarantee increased trading volume or stock price for XRTX.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 19.2, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.016619, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "alphavantage", "event_confidence": 61, "model_confidence": 0.4, "provider_symbols": ["XRTX", "XRTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "08 Sep 2026 18:51", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "XRTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOMVR6US1lQWFOMDdiQXI1VzFNVmJMZFMtaTl5Ymp5QnBwenljaFlQVVdHT25uOU5UU2xKOWJEYXAyYjhzb3JIYkdtZWxSN1NIaTktRWlQYzJzbi1MdDNFbUtMdi1UWmN6RkFpN3E5NzNKdl95QlVCalo5Vnd5Ujd1NUpzak5XUkRKU05iWkRPRnFzbVdMYnpoNk01ZzNTOUhxTklNaHFDMDlfc3JNSkVhTG5SdExfUTQ2QjZOY3k3Z0dJazg2?oc=5", "tier": "direct", "title": "XORTX Therapeutics stock gains as Nasdaq listing takes center stage", "topics": [], "summary": "", "age_days": 19.9, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "positive", "story_key": "6c106ae26035e67f467af82f96faca33fa143e22d535a8efe823d0a500a0cebf", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOMVR6US1lQWFOMDdiQXI1VzFNVmJMZFMtaTl5Ymp5QnBwenljaFlQVVdHT25uOU5UU2xKOWJEYXAyYjhzb3JIYkdtZWxSN1NIaTktRWlQYzJzbi1MdDNFbUtMdi1UWmN6RkFpN3E5NzNKdl95QlVCalo5Vnd5Ujd1NUpzak5XUkRKU05iWkRPRnFzbVdMYnpoNk01ZzNTOUhxTklNaHFDMDlfc3JNSkVhTG5SdExfUTQ2QjZOY3k3Z0dJazg2?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-09-05T12:05:55+00:00", "source_names": ["AD HOC NEWS"], "target_scope": "XORTX Therapeutics stock gains as Nasdaq listing takes center stage", "tone_signals": ["Positive financial language"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.1, "sentiment_pct": 57, "evidence_basis": "headline_only", "evidence_share": 0.5, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 7.4e-05, "influence_label": "Low", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 35, "model_confidence": 0.461, "provider_symbols": ["XRTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 28, "published_display": "05 Sep 2026 12:05", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0.5", "target_provider_symbol": "XRTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxNOU1hTUp1a0UyNkV1d011Yno5T2x3MDEzeVBENk1JaWRhVEsydHdsWFg0UERFTmd2UG1FZkxUZC1UdUpPYloxaG9BeVJ5V2RZQVZ0c2VzTkRoYldaaDZiX01mLTBBTURsc25XVmRCYU9zMm5OM19NZTlNNDFIRXpXSXFwOWpyY0k3bFI2dDM5MU1FYjVTaDVDd1VRcHl6eUhhYjZVeEVOSzhhZVZWaDNxc1dRYThzeWpuS1NHNXBwVGZ1WHRueGh6d0FfN2ZzUHFfUkdoRnM1aUlrUDhDZm9DdTNPSDFWZFczNzhfM2lUaW1SVjA?oc=5", "tier": "direct", "title": "XORTX Therapeutics Finalizes TSXV Delisting and Re-engages IR Agency in US$2.5 Million Nasdaq-Focused Campaign", "topics": [], "summary": "", "age_days": 20.8, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "neutral", "story_key": "cfc4a71ed15b29ede2fac62208c75ea10cbfd8b9c2339015b6d42789d09e5d98", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxNOU1hTUp1a0UyNkV1d011Yno5T2x3MDEzeVBENk1JaWRhVEsydHdsWFg0UERFTmd2UG1FZkxUZC1UdUpPYloxaG9BeVJ5V2RZQVZ0c2VzTkRoYldaaDZiX01mLTBBTURsc25XVmRCYU9zMm5OM19NZTlNNDFIRXpXSXFwOWpyY0k3bFI2dDM5MU1FYjVTaDVDd1VRcHl6eUhhYjZVeEVOSzhhZVZWaDNxc1dRYThzeWpuS1NHNXBwVGZ1WHRueGh6d0FfN2ZzUHFfUkdoRnM1aUlrUDhDZm9DdTNPSDFWZFczNzhfM2lUaW1SVjA?oc=5", "source_name": "TipRanks", "published_at": "2026-09-04T15:08:00+00:00", "source_names": ["TipRanks"], "target_scope": "XORTX Therapeutics Finalizes TSXV Delisting and Re-engages IR Agency in US$2.5 Million Nasdaq-Focused Campaign", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.1, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 4.6e-05, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["XRTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "04 Sep 2026 15:08", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "XRTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPWTRZRnJ4cWltSVdnbTVBQ2xQV2Y2cFdxT2dTUjF1LTlEQmllSm1VdndZNExqbWQzY09mYzJXWGFoTHl2dmZBZnZvdTkydERmclEzcTMtdGo3V0lNcFRhMWF0d2k0ZV9GSEZpNDJseVNva2YtWU5ucjFnNjFFdWFSRzZnbHRFall3X3FWQ3RDenBGNnlXcHB5OEVWMi1MRThFdWRibFdTMWhKQ1dRRTNHU29yUncxeDZoY3hzX1BmMzUwenBCOW52Tg?oc=5", "tier": "direct", "title": "XORTX Therapeutics (XRTX) Advances 2.94% to $2.17 as Traders Eye Move Toward $2.28 Resistance - Overbought Signal Alerts", "topics": [], "summary": "", "age_days": 21.8, "is_stale": false, "provider": "google_news", "providers": ["google_news"], "sentiment": "neutral", "story_key": "e7f05364a5a4062d0e3a45619616494ef8dfe5f86c51c238d14f5ec915f3a82f", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPWTRZRnJ4cWltSVdnbTVBQ2xQV2Y2cFdxT2dTUjF1LTlEQmllSm1VdndZNExqbWQzY09mYzJXWGFoTHl2dmZBZnZvdTkydERmclEzcTMtdGo3V0lNcFRhMWF0d2k0ZV9GSEZpNDJseVNva2YtWU5ucjFnNjFFdWFSRzZnbHRFall3X3FWQ3RDenBGNnlXcHB5OEVWMi1MRThFdWRibFdTMWhKQ1dRRTNHU29yUncxeDZoY3hzX1BmMzUwenBCOW52Tg?oc=5", "source_name": "siam.in", "published_at": "2026-09-03T14:46:31+00:00", "source_names": ["siam.in"], "target_scope": "XORTX Therapeutics (XRTX) Advances 2.94% to $2.17 as Traders Eye Move Toward $2.28 Resistance - Overbought Signal Alerts", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.1, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 2.8e-05, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["XRTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "03 Sep 2026 14:46", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "XRTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxOSHZJRS1pZnBQME1pX2JxOTNzaDZtUnVOTW5xb1A4SFUzQy1BT2lRXzNOR2U2d3VxQ3hMNUtZQ3ZWN2pUY1FRVml6NFAwZ0NuWDhsQUF6MFRuLWlUN01Xa1h3T0hKblVOQnV5RGY5QTJPUldIMzZsbTl2M3ZoVFh5NmRLTlp3SThKR2phTExDSmNEYzRlSGcxY0NtanVKTXFhYUFiTkl0aG42UkNNN0tCTk8wcXNaVlFqaEJTVXQ0Vm56MDQ1eXZFZV8tREtURkJjM0M1cjVORnV4TlNsTk1IRXhCMVh5QQ?oc=5", "tier": "direct", "title": "XORTX Therapeutics (TSXV:XRTX) Gains 4.59% as Kidney-Disease Pipeline and Sharper Capital Focus Support Positive Momentum", "topics": ["Earnings", "Finance", "Financial Markets", "Life Sciences"], "summary": "XORTX Therapeutics (TSXV:XRTX) rose 4.59% on August 31, 2026, driven by increased investor interest in its kidney-disease pipeline and a sharper focus on capital preservation. The company's acquisition of an anti-fibrotic kidney asset and recent financing activities, coupled with the recovery of funds from a terminated investor-relations program, have strengthened its financial position. While the outlook is cautiously constructive, the company faces significant risks related to clinical execution, regulatory approval, and the capital-intensive nature of biotechnology development.", "age_days": 24.1, "is_stale": false, "provider": "google_news", "providers": ["alphavantage", "google_news"], "sentiment": "positive", "story_key": "3bc7a7a06eb6b2849d870de5cbce0b0ab60a1cdb1e756b45f9195d31ebf6d870", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxOSHZJRS1pZnBQME1pX2JxOTNzaDZtUnVOTW5xb1A4SFUzQy1BT2lRXzNOR2U2d3VxQ3hMNUtZQ3ZWN2pUY1FRVml6NFAwZ0NuWDhsQUF6MFRuLWlUN01Xa1h3T0hKblVOQnV5RGY5QTJPUldIMzZsbTl2M3ZoVFh5NmRLTlp3SThKR2phTExDSmNEYzRlSGcxY0NtanVKTXFhYUFiTkl0aG42UkNNN0tCTk8wcXNaVlFqaEJTVXQ0Vm56MDQ1eXZFZV8tREtURkJjM0M1cjVORnV4TlNsTk1IRXhCMVh5QQ?oc=5", "source_name": "kalkine.ca", "published_at": "2026-09-01T07:54:00+00:00", "source_names": ["kalkine.ca"], "target_scope": "XORTX Therapeutics (TSXV:XRTX) Gains 4.59% as Kidney-Disease Pipeline and Sharper Capital Focus Support Positive Momentum XORTX Therapeutics (TSXV:XRTX) rose 4.59% on August 31, 2026, driven by increased investor interest in its kidney-disease pipeline and a sharper focus on capital preservation.", "tone_signals": ["Regulatory Approval"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 3.5, "sentiment_pct": 71, "evidence_basis": "archived_article", "evidence_share": 59.8, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.008655, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.621, "provider_symbols": ["XRTX", "XRTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 51, "published_display": "01 Sep 2026 07:54", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "59.8", "target_provider_symbol": "XRTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://www.tipranks.com/news/company-announcements/xortx-terminates-ir-agreement-postpones-marketing-amid-tsxv-delisting", "tier": "direct", "title": "XORTX Terminates IR Agreement, Postpones Marketing Amid TSXV Delisting", "topics": ["Earnings", "Finance", "Life Sciences"], "summary": "XORTX Therapeutics Inc. has terminated its investor relations agreement with IR Agency LLC, recovering a US$2.5 million prepaid fee. The company is postponing its marketing efforts and pursuing a voluntary delisting from the TSX Venture Exchange, effective September 1, 2026, to focus on business and clinical development. Additionally, XORTX corrected a prior disclosure regarding a US$240,000 finder's fee related to an acquisition.", "age_days": 27.4, "is_stale": false, "provider": "archive", "providers": ["alphavantage", "archive"], "sentiment": "neutral", "story_key": "1e7f317b6f4c16de55fc86d0b04d63ff693e68b4a1cc35be6353da8b046f74d8", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://www.tipranks.com/news/company-announcements/xortx-terminates-ir-agreement-postpones-marketing-amid-tsxv-delisting", "source_name": "TipRanks", "published_at": "2026-08-29T00:37:11+00:00", "source_names": ["TipRanks"], "target_scope": "XORTX Terminates IR Agreement, Postpones Marketing Amid TSXV Delisting XORTX Therapeutics Inc. Additionally, XORTX corrected a prior disclosure regarding a US$240,000 finder's fee related to an acquisition.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 6.6, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.006681, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "alphavantage", "event_confidence": 77, "model_confidence": 0.4, "provider_symbols": ["XRTX", "XRTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "29 Aug 2026 00:37", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "XRTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNcTBrazllWEp1SXQxRTZnQ0R6ZENwTjRQNF9OSTNZcVAwcUN1NVlROFFSQzZoWUhyVERtUVVaS3VPZFRoRWhxTmg2NktKOVpNNVp3dmdiTHl2LVBmU1NPM0VheTY3Q0cwOGFtSUdIWjR4QUh5d2loM2RBa1N1LWVnTG5uS1V2V0p5d3F3NDJ5ZlhHWjV1dkVqVVprdkRQRTVPc2VXc3lnbHFkZUdrek5HTkkwZXpvbDByWkE?oc=5", "tier": "direct", "title": "XORTX Therapeutics (XRTX) to leave TSXV, delays $2.5M IR campaign", "topics": [], "summary": "", "age_days": 27.9, "is_stale": false, "provider": "archive", "providers": ["archive", "google_news"], "sentiment": "neutral", "story_key": "df3223882ad27a24b9f56977deda3d07352d742fb0438974cc046be2edb8464e", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNcTBrazllWEp1SXQxRTZnQ0R6ZENwTjRQNF9OSTNZcVAwcUN1NVlROFFSQzZoWUhyVERtUVVaS3VPZFRoRWhxTmg2NktKOVpNNVp3dmdiTHl2LVBmU1NPM0VheTY3Q0cwOGFtSUdIWjR4QUh5d2loM2RBa1N1LWVnTG5uS1V2V0p5d3F3NDJ5ZlhHWjV1dkVqVVprdkRQRTVPc2VXc3lnbHFkZUdrek5HTkkwZXpvbDByWkE?oc=5", "source_name": "Stock Titan", "published_at": "2026-08-28T12:45:39+00:00", "source_names": ["Stock Titan"], "target_scope": "XORTX Therapeutics (XRTX) to leave TSXV, delays $2.5M IR campaign", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 3e-06, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["XRTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "28 Aug 2026 12:45", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "XRTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://www.globenewswire.com/news-release/2026/08/28/3352627/0/en/xortx-announces-termination-and-postponement-of-investor-relations-program.html", "tier": "direct", "title": "XORTX Announces Termination and Postponement of Investor Relations Program", "topics": ["Finance", "Life Sciences"], "summary": "XORTX Therapeutics Inc. has terminated its investor relations agreement with IR Agency LLC and postponed its marketing program. This decision was made to reduce regulatory complexity and focus resources while the company voluntarily delists from the TSX Venture Exchange, a process expected to complete by September 1, 2026. XORTX also disclosed finder's fees paid for a previous acquisition and announced a change in its transfer agent.", "age_days": 28.1, "is_stale": false, "provider": "archive", "providers": ["alphavantage", "archive"], "sentiment": "neutral", "story_key": "f5cdff39387a7bc9873cb5d8e963969dac4f0bebc83bdfb139427c7c82d87c34", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "press_release", "source_link": "https://www.globenewswire.com/news-release/2026/08/28/3352627/0/en/xortx-announces-termination-and-postponement-of-investor-relations-program.html", "source_name": "GlobeNewswire", "published_at": "2026-08-28T07:00:00+00:00", "source_names": ["GlobeNewswire"], "target_scope": "XORTX Announces Termination and Postponement of Investor Relations Program XORTX Therapeutics Inc. XORTX also disclosed finder's fees paid for a previous acquisition and announced a change in its transfer agent.", "tone_signals": ["Negative financial language"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 6.2, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.006789, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "alphavantage", "event_confidence": 77, "model_confidence": 0.45, "provider_symbols": ["ANU", "XRTX", "XRTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "28 Aug 2026 07:00", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "XRTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPWVQwV09QVHlIMTNXbmFsd1htbXBZY1Zxd29KNkR6ejBzSlZJT1MtLXdSdl9VSFBzRzgtaldhS09HY3hGVlV3TXd3d095blpUeEQwclNpb3NtTWUtclVNZnBEeUpFdWpRM0RSSjFPUUlSY0JpMUU3SHI0UEpTdU1UNTljS1NDaVo4WllZUFFaWjdHMFJCX0xoMnE1M1RtV0Vqak9ZdGlscFM5S3M?oc=5", "tier": "direct", "title": "XORTX Therapeutics Inc. (XRTX) Peer Comparison \u2013 Compare with Others", "topics": [], "summary": "", "age_days": 28.6, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "neutral", "story_key": "05bf28ad8e210870ac472815999021f4f2ca2aba1ba57f1be154e54054db51c7", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPWVQwV09QVHlIMTNXbmFsd1htbXBZY1Zxd29KNkR6ejBzSlZJT1MtLXdSdl9VSFBzRzgtaldhS09HY3hGVlV3TXd3d095blpUeEQwclNpb3NtTWUtclVNZnBEeUpFdWpRM0RSSjFPUUlSY0JpMUU3SHI0UEpTdU1UNTljS1NDaVo4WllZUFFaWjdHMFJCX0xoMnE1M1RtV0Vqak9ZdGlscFM5S3M?oc=5", "source_name": "Value Research", "published_at": "2026-08-27T20:01:00+00:00", "source_names": ["Value Research"], "target_scope": "XORTX Therapeutics Inc. (XRTX) Peer Comparison \u2013 Compare with Others", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 3e-06, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["XRTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "27 Aug 2026 20:01", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "XRTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPZFRHLUtFR1dlZ05YN1RHc2NGQ2pjRG85dWlfR19nc2Q0aUdtRHpjbk9LbkhfWmlDa25tbXNHYkdBMmp0bmJUcHQteER6UWl2QUROZFgzTjhaSE0teGdnZmd6SVR0TzIwNVhKXzVXMGxRenZpY3YzcF9DcUFjNWZaMk1aMkoxR2xGS2JQNF9mbUVIQ2cxYTBfR2g2VDlXT1lMWnZpQg?oc=5", "tier": "direct", "title": "XORTX Therapeutics Inc. (XRTX) Key Financial Ratios \u2013 Valuation, Profitability & More", "topics": [], "summary": "", "age_days": 28.6, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "neutral", "story_key": "cc4cddec760fa0ad69db687265957c2d1c21929e56776f717ab76c39f64bfd9a", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPZFRHLUtFR1dlZ05YN1RHc2NGQ2pjRG85dWlfR19nc2Q0aUdtRHpjbk9LbkhfWmlDa25tbXNHYkdBMmp0bmJUcHQteER6UWl2QUROZFgzTjhaSE0teGdnZmd6SVR0TzIwNVhKXzVXMGxRenZpY3YzcF9DcUFjNWZaMk1aMkoxR2xGS2JQNF9mbUVIQ2cxYTBfR2g2VDlXT1lMWnZpQg?oc=5", "source_name": "Value Research", "published_at": "2026-08-27T20:01:00+00:00", "source_names": ["Value Research"], "target_scope": "XORTX Therapeutics Inc. (XRTX) Key Financial Ratios \u2013 Valuation, Profitability & More", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 3e-06, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["XRTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "27 Aug 2026 20:01", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "XRTX.ARCHIVE", "provider_directional_mass": null}], "industry": [], "sector": []}, "detail_intelligence": {"headline": "Early balanced news score", "summary": "24 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.", "status": "provisional", "metrics": [{"label": "News score", "value": 50, "display": "50", "tone": "neutral", "note": "Early balanced news score"}, {"label": "Confidence", "value": 16, "display": "16", "tone": "negative", "note": "thin evidence"}, {"label": "Company news", "value": 100, "display": "100%", "tone": "positive", "note": "24 company stories"}, {"label": "Story agreement", "value": 93, "display": "93", "tone": "positive", "note": "7/100 difference"}], "confidence_drivers": [{"label": "Amount of evidence", "value": 0, "note": "0.014 after freshness weighting"}, {"label": "Source breadth", "value": 60, "note": "3 independent publishers"}, {"label": "Company relevance", "value": 100, "note": "share tied directly to this company"}, {"label": "Freshness", "value": 18, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 93, "note": "how closely stories agree"}, {"label": "Publisher mix", "value": 48, "note": "less reliance on one publisher"}], "freshness": 18, "source_independence": 48, "timeline": [{"date": "2026-08-29", "label": "29 Aug", "count": 1, "score": 50, "tone": "neutral", "x": 42.0, "y": 135.0, "volume_height": 10.4, "volume_y": 255.6}, {"date": "2026-08-30", "label": "30 Aug", "count": 0, "score": null, "tone": "neutral", "x": 73.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-31", "label": "31 Aug", "count": 0, "score": null, "tone": "neutral", "x": 105.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-01", "label": "01 Sep", "count": 1, "score": 71, "tone": "positive", "x": 136.8, "y": 96.8, "volume_height": 10.4, "volume_y": 255.6}, {"date": "2026-09-02", "label": "02 Sep", "count": 0, "score": null, "tone": "neutral", "x": 168.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-03", "label": "03 Sep", "count": 1, "score": 50, "tone": "neutral", "x": 199.9, "y": 135.0, "volume_height": 10.4, "volume_y": 255.6}, {"date": "2026-09-04", "label": "04 Sep", "count": 1, "score": 50, "tone": "neutral", "x": 231.5, "y": 135.0, "volume_height": 10.4, "volume_y": 255.6}, {"date": "2026-09-05", "label": "05 Sep", "count": 1, "score": 57, "tone": "neutral", "x": 263.1, "y": 122.3, "volume_height": 10.4, "volume_y": 255.6}, {"date": "2026-09-06", "label": "06 Sep", "count": 0, "score": null, "tone": "neutral", "x": 294.7, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-07", "label": "07 Sep", "count": 0, "score": null, "tone": "neutral", "x": 326.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-08", "label": "08 Sep", "count": 1, "score": 50, "tone": "neutral", "x": 357.9, "y": 135.0, "volume_height": 10.4, "volume_y": 255.6}, {"date": "2026-09-09", "label": "09 Sep", "count": 3, "score": 50, "tone": "neutral", "x": 389.4, "y": 135.0, "volume_height": 31.2, "volume_y": 234.8}, {"date": "2026-09-10", "label": "10 Sep", "count": 2, "score": 50, "tone": "neutral", "x": 421.0, "y": 135.0, "volume_height": 20.8, "volume_y": 245.2}, {"date": "2026-09-11", "label": "11 Sep", "count": 3, "score": 50, "tone": "neutral", "x": 452.6, "y": 135.0, "volume_height": 31.2, "volume_y": 234.8}, {"date": "2026-09-12", "label": "12 Sep", "count": 0, "score": null, "tone": "neutral", "x": 484.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-13", "label": "13 Sep", "count": 0, "score": null, "tone": "neutral", "x": 515.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-14", "label": "14 Sep", "count": 0, "score": null, "tone": "neutral", "x": 547.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-15", "label": "15 Sep", "count": 0, "score": null, "tone": "neutral", "x": 579.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-16", "label": "16 Sep", "count": 1, "score": 58, "tone": "positive", "x": 610.6, "y": 120.4, "volume_height": 10.4, "volume_y": 255.6}, {"date": "2026-09-17", "label": "17 Sep", "count": 0, "score": null, "tone": "neutral", "x": 642.1, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-18", "label": "18 Sep", "count": 5, "score": 50, "tone": "neutral", "x": 673.7, "y": 135.0, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-09-19", "label": "19 Sep", "count": 0, "score": null, "tone": "neutral", "x": 705.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-20", "label": "20 Sep", "count": 0, "score": null, "tone": "neutral", "x": 736.9, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-21", "label": "21 Sep", "count": 0, "score": null, "tone": "neutral", "x": 768.5, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-22", "label": "22 Sep", "count": 0, "score": null, "tone": "neutral", "x": 800.1, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-23", "label": "23 Sep", "count": 0, "score": null, "tone": "neutral", "x": 831.7, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-24", "label": "24 Sep", "count": 0, "score": null, "tone": "neutral", "x": 863.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-25", "label": "25 Sep", "count": 0, "score": null, "tone": "neutral", "x": 894.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-26", "label": "26 Sep", "count": 0, "score": null, "tone": "neutral", "x": 926.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-27", "label": "27 Sep", "count": 0, "score": null, "tone": "neutral", "x": 958.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}], "timeline_points": "42.0,135.0 136.8,96.8 199.9,135.0 231.5,135.0 263.1,122.3 357.9,135.0 389.4,135.0 421.0,135.0 452.6,135.0 610.6,120.4 673.7,135.0", "timeline_has_signal": true, "timeline_start": "29 Aug", "timeline_mid": "13 Sep", "timeline_end": "27 Sep", "momentum": {"label": "Cooling", "tone": "neutral", "recent_score": null, "prior_score": null, "delta": null, "recent_count": 0, "prior_count": 0, "volume_delta": 0, "reliable": false, "reliability_note": "Thin comparison; direction is not yet confirmed"}, "early_change": {"label": "No new story in 24 hours", "tone": "neutral", "latest_score": null, "baseline_score": null, "delta": null, "latest_count": 0, "baseline_count": 0, "confirmed": false, "note": "A comparison needs current and earlier-week company news"}, "freshness_buckets": [{"label": "Last 24 hours", "count": 0, "share": 0}, {"label": "1 to 3 days", "count": 0, "share": 0}, {"label": "4 to 7 days", "count": 0, "share": 0}, {"label": "8 to 14 days", "count": 6, "share": 25}, {"label": "15 to 21 days", "count": 9, "share": 38}, {"label": "22 to 30 days", "count": 7, "share": 29}], "source_profile": [{"label": "Stock Titan", "count": 4, "share": 17, "score": 50, "tone": "neutral"}, {"label": "kalkine.ca", "count": 3, "share": 12, "score": 69, "tone": "positive"}, {"label": "GlobeNewswire", "count": 3, "share": 12, "score": 50, "tone": "neutral"}, {"label": "TipRanks", "count": 2, "share": 8, "score": 50, "tone": "neutral"}, {"label": "Value Research", "count": 2, "share": 8, "score": 50, "tone": "neutral"}, {"label": "Benzinga", "count": 1, "share": 4, "score": 58, "tone": "positive"}, {"label": "AD HOC NEWS", "count": 1, "share": 4, "score": 57, "tone": "neutral"}], "event_profile": [{"label": "Market update", "count": 17, "share": 71, "score": 52, "tone": "neutral"}, {"label": "Earnings", "count": 3, "share": 12, "score": 52, "tone": "neutral"}, {"label": "Deals and strategy", "count": 3, "share": 12, "score": 50, "tone": "neutral"}, {"label": "Regulatory and legal", "count": 1, "share": 4, "score": 50, "tone": "neutral"}], "topics": [{"label": "Life Sciences", "count": 12, "share": 50}, {"label": "Finance", "count": 7, "share": 29}, {"label": "Financial Markets", "count": 6, "share": 25}, {"label": "Earnings", "count": 4, "share": 17}, {"label": "Manufacturing", "count": 3, "share": 12}], "supporting": [{"label": "Direct evidence", "text": "24 current stories are mapped specifically to XRTX."}, {"label": "Source breadth", "text": "The score uses 3 publishers rather than depending on one outlet."}], "tempering": [{"label": "Too little evidence", "text": "The stories agree, but freshness-weighted evidence is only 0.014."}, {"label": "Confidence", "text": "Confidence is 16/100, below the threshold for a firm score."}], "supporting_heading": "What supports the score", "tempering_heading": "What limits the score", "latest_observation": {"url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE96OHJmU3ZWUXM2Y0drcmwtMzdHRnUtMmg2ejV0Y3ZvMEhtTHJUSVF0c010OS1xeTRHWWtyLXlBUXM4RGtfeDhRQ2hxdGo5N1VYS1djclJB?oc=5", "tier": "direct", "title": "XORTX Therapeutics Inc (NASDAQ: XRTX) Stock Price, News & Analysis", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "This article provides an overview of XORTX Therapeutics Inc (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on hyperuricemia-related diseases. It details their drug pipeline, including treatments for gout, autosomal dominant polycystic kidney disease, acute kidney injury, and type 2 diabetic nephropathy. The company's key financial metrics, income statements, balance sheets, and cash flow breakdowns for recent years are also presented, alongside a peer comparison in the biotechnology sector.", "age_days": 6.6, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE96OHJmU3ZWUXM2Y0drcmwtMzdHRnUtMmg2ejV0Y3ZvMEhtTHJUSVF0c010OS1xeTRHWWtyLXlBUXM4RGtfeDhRQ2hxdGo5N1VYS1djclJB?oc=5", "source_name": "kalkine.com.au", "published_at": "2026-09-18T20:29:00+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 40.2, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.038561, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "18 Sep 2026 20:29", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, "article_count": 24, "updated_at": "2026-09-25T10:23:29.212866+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 153.5, "label": "03 Apr 2026", "close": 2.1475, "index": 100.0}, {"x": 78.4, "y": 115.6, "label": "10 Apr 2026", "close": 2.49, "index": 115.9}, {"x": 114.9, "y": 140.0, "label": "17 Apr 2026", "close": 2.27, "index": 105.7}, {"x": 151.3, "y": 55.8, "label": "24 Apr 2026", "close": 3.03, "index": 141.1}, {"x": 187.7, "y": 83.5, "label": "01 May 2026", "close": 2.78, "index": 129.5}, {"x": 224.2, "y": 82.4, "label": "08 May 2026", "close": 2.79, "index": 129.9}, {"x": 260.6, "y": 104.5, "label": "15 May 2026", "close": 2.59, "index": 120.6}, {"x": 297.0, "y": 149.9, "label": "22 May 2026", "close": 2.18, "index": 101.5}, {"x": 333.5, "y": 136.6, "label": "29 May 2026", "close": 2.3, "index": 107.1}, {"x": 369.9, "y": 146.6, "label": "05 Jun 2026", "close": 2.21, "index": 102.9}, {"x": 406.3, "y": 149.9, "label": "12 Jun 2026", "close": 2.18, "index": 101.5}, {"x": 442.8, "y": 159.9, "label": "19 Jun 2026", "close": 2.09, "index": 97.3}, {"x": 479.2, "y": 148.8, "label": "26 Jun 2026", "close": 2.19, "index": 102.0}, {"x": 515.6, "y": 162.1, "label": "03 Jul 2026", "close": 2.07, "index": 96.4}, {"x": 552.0, "y": 150.5, "label": "10 Jul 2026", "close": 2.175, "index": 101.3}, {"x": 588.5, "y": 168.8, "label": "17 Jul 2026", "close": 2.01, "index": 93.6}, {"x": 624.9, "y": 167.1, "label": "24 Jul 2026", "close": 2.025, "index": 94.3}, {"x": 661.3, "y": 156.6, "label": "31 Jul 2026", "close": 2.12, "index": 98.7}, {"x": 697.8, "y": 155.5, "label": "07 Aug 2026", "close": 2.13, "index": 99.2}, {"x": 734.2, "y": 152.7, "label": "14 Aug 2026", "close": 2.155, "index": 100.3}, {"x": 770.6, "y": 165.4, "label": "21 Aug 2026", "close": 2.04, "index": 95.0}, {"x": 807.1, "y": 132.4, "label": "28 Aug 2026", "close": 2.338, "index": 108.9}, {"x": 843.5, "y": 135.5, "label": "04 Sep 2026", "close": 2.31, "index": 107.6}, {"x": 879.9, "y": 133.3, "label": "11 Sep 2026", "close": 2.33, "index": 108.5}, {"x": 916.4, "y": 178.7, "label": "18 Sep 2026", "close": 1.92, "index": 89.4}, {"x": 952.8, "y": 204.2, "label": "25 Sep 2026", "close": 1.69, "index": 78.7}], "sentiment_points": [{"at": "2026-07-03T23:59:59.999Z", "date": "2026-07-03", "label": "03 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 0, "stories": 2, "close": 2.07, "price_change": -5.5, "x": 520.8, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-10T23:59:59.999Z", "date": "2026-07-10", "label": "10 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 0, "stories": 5, "close": 2.175, "price_change": 5.1, "x": 557.2, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-07-17T23:59:59.999Z", "date": "2026-07-17", "label": "17 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 0, "stories": 6, "close": 2.01, "price_change": -7.6, "x": 593.7, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "label": "24 Jul 2026", "score": 49, "tone": "neutral", "raw_score": 36, "confidence": 26, "stories": 10, "close": 2.025, "price_change": 0.7, "x": 630.1, "y": 131.8, "show_label": false, "label_y": 121.80000000000001}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "label": "31 Jul 2026", "score": 49, "tone": "neutral", "raw_score": 45, "confidence": 27, "stories": 21, "close": 2.12, "price_change": 4.7, "x": 666.5, "y": 131.8, "show_label": true, "label_y": 121.80000000000001}, {"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "label": "07 Aug 2026", "score": 52, "tone": "neutral", "raw_score": 59, "confidence": 27, "stories": 28, "close": 2.13, "price_change": 0.5, "x": 703.0, "y": 126.3, "show_label": false, "label_y": 116.3}, {"at": "2026-08-14T23:59:59.999Z", "date": "2026-08-14", "label": "14 Aug 2026", "score": 49, "tone": "neutral", "raw_score": 43, "confidence": 25, "stories": 27, "close": 2.155, "price_change": 1.2, "x": 739.4, "y": 131.8, "show_label": true, "label_y": 121.80000000000001}, {"at": "2026-08-21T23:59:59.999Z", "date": "2026-08-21", "label": "21 Aug 2026", "score": 48, "tone": "neutral", "raw_score": 37, "confidence": 24, "stories": 26, "close": 2.04, "price_change": -5.3, "x": 775.8, "y": 133.7, "show_label": false, "label_y": 123.69999999999999}, {"at": "2026-08-28T23:59:59.999Z", "date": "2026-08-28", "label": "28 Aug 2026", "score": 49, "tone": "neutral", "raw_score": 35, "confidence": 19, "stories": 18, "close": 2.338, "price_change": 14.6, "x": 812.3, "y": 131.8, "show_label": true, "label_y": 121.80000000000001}, {"at": "2026-09-04T23:59:59.999Z", "date": "2026-09-04", "label": "04 Sep 2026", "score": 52, "tone": "neutral", "raw_score": 63, "confidence": 26, "stories": 12, "close": 2.31, "price_change": -1.2, "x": 848.7, "y": 126.3, "show_label": false, "label_y": 116.3}, {"at": "2026-09-11T23:59:59.999Z", "date": "2026-09-11", "label": "11 Sep 2026", "score": 51, "tone": "neutral", "raw_score": 63, "confidence": 20, "stories": 21, "close": 2.33, "price_change": 0.9, "x": 885.1, "y": 128.2, "show_label": true, "label_y": 118.19999999999999}, {"at": "2026-09-18T23:59:59.999Z", "date": "2026-09-18", "label": "18 Sep 2026", "score": 51, "tone": "neutral", "raw_score": 64, "confidence": 20, "stories": 24, "close": 1.92, "price_change": -17.6, "x": 921.6, "y": 128.2, "show_label": false, "label_y": 118.19999999999999}, {"at": "2026-09-25T23:59:59.999Z", "date": "2026-09-25", "label": "25 Sep 2026", "score": 50, "tone": "neutral", "raw_score": 69, "confidence": 16, "stories": 24, "close": 1.69, "price_change": -12.0, "x": 958.0, "y": 130.0, "show_label": true, "label_y": 120.0}], "price_path": "42.0,153.5 78.4,115.6 114.9,140.0 151.3,55.8 187.7,83.5 224.2,82.4 260.6,104.5 297.0,149.9 333.5,136.6 369.9,146.6 406.3,149.9 442.8,159.9 479.2,148.8 515.6,162.1 552.0,150.5 588.5,168.8 624.9,167.1 661.3,156.6 697.8,155.5 734.2,152.7 770.6,165.4 807.1,132.4 843.5,135.5 879.9,133.3 916.4,178.7 952.8,204.2", "sentiment_path": "520.8,130.0 557.2,130.0 593.7,130.0 630.1,131.8 666.5,131.8 703.0,126.3 739.4,131.8 775.8,133.7 812.3,131.8 848.7,126.3 885.1,128.2 921.6,128.2 958.0,130.0", "score_version": "evidence-v10", "price_change": -21.3, "sentiment_change": 0, "recent_pairs": [{"at": "2026-09-25T23:59:59.999Z", "date": "2026-09-25", "label": "25 Sep 2026", "score": 50, "tone": "neutral", "raw_score": 69, "confidence": 16, "stories": 24, "close": 1.69, "price_change": -12.0, "x": 958.0, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-09-18T23:59:59.999Z", "date": "2026-09-18", "label": "18 Sep 2026", "score": 51, "tone": "neutral", "raw_score": 64, "confidence": 20, "stories": 24, "close": 1.92, "price_change": -17.6, "x": 921.6, "y": 128.2, "show_label": false, "label_y": 118.19999999999999}, {"at": "2026-09-11T23:59:59.999Z", "date": "2026-09-11", "label": "11 Sep 2026", "score": 51, "tone": "neutral", "raw_score": 63, "confidence": 20, "stories": 21, "close": 2.33, "price_change": 0.9, "x": 885.1, "y": 128.2, "show_label": true, "label_y": 118.19999999999999}, {"at": "2026-09-04T23:59:59.999Z", "date": "2026-09-04", "label": "04 Sep 2026", "score": 52, "tone": "neutral", "raw_score": 63, "confidence": 26, "stories": 12, "close": 2.31, "price_change": -1.2, "x": 848.7, "y": 126.3, "show_label": false, "label_y": 116.3}, {"at": "2026-08-28T23:59:59.999Z", "date": "2026-08-28", "label": "28 Aug 2026", "score": 49, "tone": "neutral", "raw_score": 35, "confidence": 19, "stories": 18, "close": 2.338, "price_change": 14.6, "x": 812.3, "y": 131.8, "show_label": true, "label_y": 121.80000000000001}, {"at": "2026-08-21T23:59:59.999Z", "date": "2026-08-21", "label": "21 Aug 2026", "score": 48, "tone": "neutral", "raw_score": 37, "confidence": 24, "stories": 26, "close": 2.04, "price_change": -5.3, "x": 775.8, "y": 133.7, "show_label": false, "label_y": 123.69999999999999}, {"at": "2026-08-14T23:59:59.999Z", "date": "2026-08-14", "label": "14 Aug 2026", "score": 49, "tone": "neutral", "raw_score": 43, "confidence": 25, "stories": 27, "close": 2.155, "price_change": 1.2, "x": 739.4, "y": 131.8, "show_label": true, "label_y": 121.80000000000001}, {"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "label": "07 Aug 2026", "score": 52, "tone": "neutral", "raw_score": 59, "confidence": 27, "stories": 28, "close": 2.13, "price_change": 0.5, "x": 703.0, "y": 126.3, "show_label": false, "label_y": 116.3}], "reconstructed": true, "latest_close": 1.69, "price_observations": 26, "sentiment_observations": 13, "sentiment_start_label": "03 Jul 2026", "sentiment_end_label": "25 Sep 2026", "sentiment_history_limited": false, "price_axis_high": 148.6, "price_axis_mid": 109.9, "price_axis_low": 71.2, "start_label": "03 Apr", "mid_label": "30 Jun", "end_label": "25 Sep", "live_score_version": "evidence-v10", "comparable_to_live": true}, "sentiment_history": [{"label": "29 Jun 23:59", "short_label": "29 Jun", "collected_at": "2026-06-29T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": null, "score_change_display": "Start", "confidence_change": null, "article_change": null, "tone": "neutral", "height": 4, "articles": 1, "confidence": 0, "evidence_status": "insufficient", "evidence_label": "Insufficient", "score_version": "evidence-v10", "reconstructed": true}, {"label": "30 Jun 23:59", "short_label": "30 Jun", "collected_at": "2026-06-30T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 2, "confidence": 0, "evidence_status": "insufficient", "evidence_label": "Insufficient", "score_version": "evidence-v10", "reconstructed": true}, {"label": "05 Jul 23:59", "short_label": "05 Jul", "collected_at": "2026-07-05T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 3, "confidence": 0, "evidence_status": "insufficient", "evidence_label": "Insufficient", "score_version": "evidence-v10", "reconstructed": true}, {"label": "09 Jul 23:59", "short_label": "09 Jul", "collected_at": "2026-07-09T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 4, "confidence": 0, "evidence_status": "insufficient", "evidence_label": "Insufficient", "score_version": "evidence-v10", "reconstructed": true}, {"label": "10 Jul 23:59", "short_label": "10 Jul", "collected_at": "2026-07-10T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 5, "confidence": 0, "evidence_status": "insufficient", "evidence_label": "Insufficient", "score_version": "evidence-v10", "reconstructed": true}, {"label": "15 Jul 23:59", "short_label": "15 Jul", "collected_at": "2026-07-15T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 6, "confidence": 0, "evidence_status": "insufficient", "evidence_label": "Insufficient", "score_version": "evidence-v10", "reconstructed": true}, {"label": "20 Jul 23:59", "short_label": "20 Jul", "collected_at": "2026-07-20T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": -2, "score_change_display": "-2", "confidence_change": 31, "article_change": 3, "tone": "neutral", "height": 4, "articles": 9, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "24 Jul 23:59", "short_label": "24 Jul", "collected_at": "2026-07-24T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 1, "score_change_display": "+1", "confidence_change": -5, "article_change": 1, "tone": "neutral", "height": 4, "articles": 10, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "26 Jul 23:59", "short_label": "26 Jul", "collected_at": "2026-07-26T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 3, "tone": "neutral", "height": 4, "articles": 13, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "27 Jul 23:59", "short_label": "27 Jul", "collected_at": "2026-07-27T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": -1, "score_change_display": "-1", "confidence_change": 5, "article_change": 4, "tone": "neutral", "height": 4, "articles": 17, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "29 Jul 23:59", "short_label": "29 Jul", "collected_at": "2026-07-29T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 1, "score_change_display": "+1", "confidence_change": 1, "article_change": 3, "tone": "neutral", "height": 4, "articles": 20, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "30 Jul 23:59", "short_label": "30 Jul", "collected_at": "2026-07-30T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 0, "tone": "neutral", "height": 4, "articles": 20, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "31 Jul 23:59", "short_label": "31 Jul", "collected_at": "2026-07-31T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 21, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "01 Aug 23:59", "short_label": "01 Aug", "collected_at": "2026-08-01T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 3, "tone": "neutral", "height": 4, "articles": 24, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "02 Aug 23:59", "short_label": "02 Aug", "collected_at": "2026-08-02T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 1, "score_change_display": "+1", "confidence_change": 4, "article_change": 2, "tone": "neutral", "height": 4, "articles": 26, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "04 Aug 23:59", "short_label": "04 Aug", "collected_at": "2026-08-04T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": -1, "score_change_display": "-1", "confidence_change": -4, "article_change": 0, "tone": "neutral", "height": 4, "articles": 26, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "05 Aug 23:59", "short_label": "05 Aug", "collected_at": "2026-08-05T23:59:59.999999+00:00", "score": 53, "delta": 3, "score_change": 4, "score_change_display": "+4", "confidence_change": 5, "article_change": 2, "tone": "neutral", "height": 6, "articles": 28, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "12 Aug 23:59", "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": -5, "score_change_display": "-5", "confidence_change": -2, "article_change": -1, "tone": "neutral", "height": 4, "articles": 27, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "13 Aug 23:59", "short_label": "13 Aug", "collected_at": "2026-08-13T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 1, "score_change_display": "+1", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 28, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "15 Aug 23:59", "short_label": "15 Aug", "collected_at": "2026-08-15T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 0, "tone": "neutral", "height": 4, "articles": 28, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "17 Aug 23:59", "short_label": "17 Aug", "collected_at": "2026-08-17T23:59:59.999999+00:00", "score": 47, "delta": -3, "score_change": -2, "score_change_display": "-2", "confidence_change": 5, "article_change": 1, "tone": "neutral", "height": 6, "articles": 29, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "27 Aug 23:59", "short_label": "27 Aug", "collected_at": "2026-08-27T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 2, "score_change_display": "+2", "confidence_change": -9, "article_change": -9, "tone": "neutral", "height": 4, "articles": 20, "confidence": 20, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "28 Aug 23:59", "short_label": "28 Aug", "collected_at": "2026-08-28T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": -2, "tone": "neutral", "height": 4, "articles": 18, "confidence": 19, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "29 Aug 23:59", "short_label": "29 Aug", "collected_at": "2026-08-29T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 0, "tone": "neutral", "height": 4, "articles": 18, "confidence": 19, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "01 Sep 23:59", "short_label": "01 Sep", "collected_at": "2026-09-01T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 3, "score_change_display": "+3", "confidence_change": 10, "article_change": -5, "tone": "neutral", "height": 4, "articles": 13, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "03 Sep 23:59", "short_label": "03 Sep", "collected_at": "2026-09-03T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 0, "tone": "neutral", "height": 4, "articles": 13, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "04 Sep 23:59", "short_label": "04 Sep", "collected_at": "2026-09-04T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": -1, "tone": "neutral", "height": 4, "articles": 12, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "05 Sep 23:59", "short_label": "05 Sep", "collected_at": "2026-09-05T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 13, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "08 Sep 23:59", "short_label": "08 Sep", "collected_at": "2026-09-08T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": -5, "article_change": 1, "tone": "neutral", "height": 4, "articles": 14, "confidence": 22, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "09 Sep 23:59", "short_label": "09 Sep", "collected_at": "2026-09-09T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 4, "tone": "neutral", "height": 4, "articles": 18, "confidence": 21, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "10 Sep 23:59", "short_label": "10 Sep", "collected_at": "2026-09-10T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 19, "confidence": 21, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "11 Sep 23:59", "short_label": "11 Sep", "collected_at": "2026-09-11T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 2, "tone": "neutral", "height": 4, "articles": 21, "confidence": 20, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "16 Sep 23:59", "short_label": "16 Sep", "collected_at": "2026-09-16T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": 5, "article_change": -2, "tone": "neutral", "height": 4, "articles": 19, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "18 Sep 23:59", "short_label": "18 Sep", "collected_at": "2026-09-18T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -5, "article_change": 5, "tone": "neutral", "height": 4, "articles": 24, "confidence": 20, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "27 Sep 05:17", "short_label": "27 Sep", "collected_at": "2026-09-27T05:17:46.064092+00:00", "score": 50, "delta": 0, "score_change": -1, "score_change_display": "-1", "confidence_change": -4, "article_change": -2, "tone": "neutral", "height": 4, "articles": 22, "confidence": 16, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}], "sentiment_history_insight": {"available": true, "series_version": "evidence-v10", "live_version": "evidence-v10", "comparable_to_live": true, "reconstructed": true, "observations": 35, "span_label": "89 days", "first_score": 50, "latest_score": 50, "net_change": 0, "net_change_display": "+0", "direction": "Broadly stable", "high_score": 53, "low_score": 47, "latest_confidence": 16, "confidence_change": 16, "latest_articles": 22, "article_change": 21, "latest_label": "27 Sep 05:17", "latest_evidence_label": "Provisional", "chart_rows": [{"label": "29 Jun 23:59", "short_label": "29 Jun", "collected_at": "2026-06-29T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": null, "score_change_display": "Start", "confidence_change": null, "article_change": null, "tone": "neutral", "height": 4, "articles": 1, "confidence": 0, "evidence_status": "insufficient", "evidence_label": "Insufficient", "score_version": "evidence-v10", "reconstructed": true, "x": 42.0, "y": 135.0}, {"label": "30 Jun 23:59", "short_label": "30 Jun", "collected_at": "2026-06-30T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 2, "confidence": 0, "evidence_status": "insufficient", "evidence_label": "Insufficient", "score_version": "evidence-v10", "reconstructed": true, "x": 68.9, "y": 135.0}, {"label": "05 Jul 23:59", "short_label": "05 Jul", "collected_at": "2026-07-05T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 3, "confidence": 0, "evidence_status": "insufficient", "evidence_label": "Insufficient", "score_version": "evidence-v10", "reconstructed": true, "x": 95.9, "y": 135.0}, {"label": "09 Jul 23:59", "short_label": "09 Jul", "collected_at": "2026-07-09T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 4, "confidence": 0, "evidence_status": "insufficient", "evidence_label": "Insufficient", "score_version": "evidence-v10", "reconstructed": true, "x": 122.8, "y": 135.0}, {"label": "10 Jul 23:59", "short_label": "10 Jul", "collected_at": "2026-07-10T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 5, "confidence": 0, "evidence_status": "insufficient", "evidence_label": "Insufficient", "score_version": "evidence-v10", "reconstructed": true, "x": 149.8, "y": 135.0}, {"label": "15 Jul 23:59", "short_label": "15 Jul", "collected_at": "2026-07-15T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 6, "confidence": 0, "evidence_status": "insufficient", "evidence_label": "Insufficient", "score_version": "evidence-v10", "reconstructed": true, "x": 176.7, "y": 135.0}, {"label": "20 Jul 23:59", "short_label": "20 Jul", "collected_at": "2026-07-20T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": -2, "score_change_display": "-2", "confidence_change": 31, "article_change": 3, "tone": "neutral", "height": 4, "articles": 9, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 203.6, "y": 138.6}, {"label": "24 Jul 23:59", "short_label": "24 Jul", "collected_at": "2026-07-24T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 1, "score_change_display": "+1", "confidence_change": -5, "article_change": 1, "tone": "neutral", "height": 4, "articles": 10, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 230.6, "y": 136.8}, {"label": "26 Jul 23:59", "short_label": "26 Jul", "collected_at": "2026-07-26T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 3, "tone": "neutral", "height": 4, "articles": 13, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 257.5, "y": 136.8}, {"label": "27 Jul 23:59", "short_label": "27 Jul", "collected_at": "2026-07-27T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": -1, "score_change_display": "-1", "confidence_change": 5, "article_change": 4, "tone": "neutral", "height": 4, "articles": 17, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 284.5, "y": 138.6}, {"label": "29 Jul 23:59", "short_label": "29 Jul", "collected_at": "2026-07-29T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 1, "score_change_display": "+1", "confidence_change": 1, "article_change": 3, "tone": "neutral", "height": 4, "articles": 20, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 311.4, "y": 136.8}, {"label": "30 Jul 23:59", "short_label": "30 Jul", "collected_at": "2026-07-30T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 0, "tone": "neutral", "height": 4, "articles": 20, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 338.4, "y": 136.8}, {"label": "31 Jul 23:59", "short_label": "31 Jul", "collected_at": "2026-07-31T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 21, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 365.3, "y": 136.8}, {"label": "01 Aug 23:59", "short_label": "01 Aug", "collected_at": "2026-08-01T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 3, "tone": "neutral", "height": 4, "articles": 24, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 392.2, "y": 136.8}, {"label": "02 Aug 23:59", "short_label": "02 Aug", "collected_at": "2026-08-02T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 1, "score_change_display": "+1", "confidence_change": 4, "article_change": 2, "tone": "neutral", "height": 4, "articles": 26, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 419.2, "y": 135.0}, {"label": "04 Aug 23:59", "short_label": "04 Aug", "collected_at": "2026-08-04T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": -1, "score_change_display": "-1", "confidence_change": -4, "article_change": 0, "tone": "neutral", "height": 4, "articles": 26, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 446.1, "y": 136.8}, {"label": "05 Aug 23:59", "short_label": "05 Aug", "collected_at": "2026-08-05T23:59:59.999999+00:00", "score": 53, "delta": 3, "score_change": 4, "score_change_display": "+4", "confidence_change": 5, "article_change": 2, "tone": "neutral", "height": 6, "articles": 28, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 473.1, "y": 129.5}, {"label": "12 Aug 23:59", "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": -5, "score_change_display": "-5", "confidence_change": -2, "article_change": -1, "tone": "neutral", "height": 4, "articles": 27, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 500.0, "y": 138.6}, {"label": "13 Aug 23:59", "short_label": "13 Aug", "collected_at": "2026-08-13T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 1, "score_change_display": "+1", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 28, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 526.9, "y": 136.8}, {"label": "15 Aug 23:59", "short_label": "15 Aug", "collected_at": "2026-08-15T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 0, "tone": "neutral", "height": 4, "articles": 28, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 553.9, "y": 136.8}, {"label": "17 Aug 23:59", "short_label": "17 Aug", "collected_at": "2026-08-17T23:59:59.999999+00:00", "score": 47, "delta": -3, "score_change": -2, "score_change_display": "-2", "confidence_change": 5, "article_change": 1, "tone": "neutral", "height": 6, "articles": 29, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 580.8, "y": 140.5}, {"label": "27 Aug 23:59", "short_label": "27 Aug", "collected_at": "2026-08-27T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 2, "score_change_display": "+2", "confidence_change": -9, "article_change": -9, "tone": "neutral", "height": 4, "articles": 20, "confidence": 20, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 607.8, "y": 136.8}, {"label": "28 Aug 23:59", "short_label": "28 Aug", "collected_at": "2026-08-28T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": -2, "tone": "neutral", "height": 4, "articles": 18, "confidence": 19, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 634.7, "y": 136.8}, {"label": "29 Aug 23:59", "short_label": "29 Aug", "collected_at": "2026-08-29T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 0, "tone": "neutral", "height": 4, "articles": 18, "confidence": 19, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 661.6, "y": 136.8}, {"label": "01 Sep 23:59", "short_label": "01 Sep", "collected_at": "2026-09-01T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 3, "score_change_display": "+3", "confidence_change": 10, "article_change": -5, "tone": "neutral", "height": 4, "articles": 13, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 688.6, "y": 131.4}, {"label": "03 Sep 23:59", "short_label": "03 Sep", "collected_at": "2026-09-03T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 0, "tone": "neutral", "height": 4, "articles": 13, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 715.5, "y": 131.4}, {"label": "04 Sep 23:59", "short_label": "04 Sep", "collected_at": "2026-09-04T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": -1, "tone": "neutral", "height": 4, "articles": 12, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 742.5, "y": 131.4}, {"label": "05 Sep 23:59", "short_label": "05 Sep", "collected_at": "2026-09-05T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 13, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 769.4, "y": 131.4}, {"label": "08 Sep 23:59", "short_label": "08 Sep", "collected_at": "2026-09-08T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": -5, "article_change": 1, "tone": "neutral", "height": 4, "articles": 14, "confidence": 22, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 796.4, "y": 133.2}, {"label": "09 Sep 23:59", "short_label": "09 Sep", "collected_at": "2026-09-09T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 4, "tone": "neutral", "height": 4, "articles": 18, "confidence": 21, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 823.3, "y": 133.2}, {"label": "10 Sep 23:59", "short_label": "10 Sep", "collected_at": "2026-09-10T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 19, "confidence": 21, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 850.2, "y": 133.2}, {"label": "11 Sep 23:59", "short_label": "11 Sep", "collected_at": "2026-09-11T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 2, "tone": "neutral", "height": 4, "articles": 21, "confidence": 20, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 877.2, "y": 133.2}, {"label": "16 Sep 23:59", "short_label": "16 Sep", "collected_at": "2026-09-16T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": 5, "article_change": -2, "tone": "neutral", "height": 4, "articles": 19, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 904.1, "y": 133.2}, {"label": "18 Sep 23:59", "short_label": "18 Sep", "collected_at": "2026-09-18T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -5, "article_change": 5, "tone": "neutral", "height": 4, "articles": 24, "confidence": 20, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 931.1, "y": 133.2}, {"label": "27 Sep 05:17", "short_label": "27 Sep", "collected_at": "2026-09-27T05:17:46.064092+00:00", "score": 50, "delta": 0, "score_change": -1, "score_change_display": "-1", "confidence_change": -4, "article_change": -2, "tone": "neutral", "height": 4, "articles": 22, "confidence": 16, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 958.0, "y": 135.0}], "chart_points": "42.0,135.0 68.9,135.0 95.9,135.0 122.8,135.0 149.8,135.0 176.7,135.0 203.6,138.6 230.6,136.8 257.5,136.8 284.5,138.6 311.4,136.8 338.4,136.8 365.3,136.8 392.2,136.8 419.2,135.0 446.1,136.8 473.1,129.5 500.0,138.6 526.9,136.8 553.9,136.8 580.8,140.5 607.8,136.8 634.7,136.8 661.6,136.8 688.6,131.4 715.5,131.4 742.5,131.4 769.4,131.4 796.4,133.2 823.3,133.2 850.2,133.2 877.2,133.2 904.1,133.2 931.1,133.2 958.0,135.0", "changes": [{"label": "27 Sep 05:17", "short_label": "27 Sep", "collected_at": "2026-09-27T05:17:46.064092+00:00", "score": 50, "delta": 0, "score_change": -1, "score_change_display": "-1", "confidence_change": -4, "article_change": -2, "tone": "neutral", "height": 4, "articles": 22, "confidence": 16, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "18 Sep 23:59", "short_label": "18 Sep", "collected_at": "2026-09-18T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -5, "article_change": 5, "tone": "neutral", "height": 4, "articles": 24, "confidence": 20, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "16 Sep 23:59", "short_label": "16 Sep", "collected_at": "2026-09-16T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": 5, "article_change": -2, "tone": "neutral", "height": 4, "articles": 19, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "11 Sep 23:59", "short_label": "11 Sep", "collected_at": "2026-09-11T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 2, "tone": "neutral", "height": 4, "articles": 21, "confidence": 20, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "10 Sep 23:59", "short_label": "10 Sep", "collected_at": "2026-09-10T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 19, "confidence": 21, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "09 Sep 23:59", "short_label": "09 Sep", "collected_at": "2026-09-09T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 4, "tone": "neutral", "height": 4, "articles": 18, "confidence": 21, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "08 Sep 23:59", "short_label": "08 Sep", "collected_at": "2026-09-08T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": -5, "article_change": 1, "tone": "neutral", "height": 4, "articles": 14, "confidence": 22, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "05 Sep 23:59", "short_label": "05 Sep", "collected_at": "2026-09-05T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 13, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}]}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}